



[www.pdr.net](http://www.pdr.net)

---

PHYSICIANS'

---

DESK

---

REFERENCE®

---



# PHYSICIANS' DESK REFERENCE®

---

**Senior Vice President, Directory Services:** Paul Walsh

**Vice President, Sales and Marketing:** Dikran N. Barsamian

**National Sales Manager, Custom Sales:** Anthony Sorce

**Senior Account Manager:** Frank Karkowsky

**Account Managers:**

Marion Gray, RPh

Lawrence C. Keary

Suzanne E. Yarrow, RN

**National Sales Manager, Medical Economics Trade Sales:**

Bill Gaffney

**Senior Business Manager:** Mark S. Ritchin

**Financial Analyst:** Wayne M. Soltis

**Vice President, Clinical Communications and**

**New Business Development:** Mukesh Mehta, RPh

**New Business Development Manager:** Jeffrey D. Dubin

**Manager, Drug Information Services:** Thomas Fleming, RPh

**Drug Information Specialists:** Maria Deutsch, MS, PharmD, CDE;

Christine Wyble, PharmD

**Editor, Directory Services:** David W. Sifton

**Project Manager:** Edward P. Connor

**Senior Associate Editor:** Lori Murray

**Assistant Editor:** Gwynned L. Kelly

**Director of Direct Marketing:** Michael Bennett

**Direct Mail Manager:** Lorraine M. Loening

**Senior Marketing Analyst:** Dina A. Maeder

**Director of Production:** Carrie Williams

**Data Manager:** Jeffrey D. Schaefer

**Production Manager:** Amy Brooks

**Production Coordinators:** Gianna Caradonna, Dee Ann DeRuvo,  
Melissa Katz

**Index Supervisor:** Johanna M. Mazur

**Index Editor:** Shannon Reilly

**Art Associate:** Joan K. Akerlind

**Digital Imaging Supervisor:** Shawn W. Cahill

**Digital Imaging Coordinator:** Frank J. McElroy, III

**Pharmaceutical Coordinator:** Mary Kaadan

**Electronic Publishing Designer:** Livio Udina

**Fulfillment Managers:** Louis J. Bolcik, Stephanie DeNardi

---

**MEDICAL ECONOMICS**

**THOMSON HEALTHCARE**

Copyright © 2001 and published by Medical Economics Company, Inc. at Montvale, NJ 07645-1742. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher.

PHYSICIANS' DESK REFERENCE®, PDR®, Pocket PDR®, The PDR® Family Guide to Prescription Drugs®, The PDR® Family Guide to Women's Health and Prescription Drugs®, and The PDR® Family Guide to Nutrition and Health® are registered trademarks used herein under license. PDR for Ophthalmic Medicines™, PDR for Nonprescription Drugs and Dietary Supplements™, PDR Companion Guide™, PDR Pharmacopoeia™ Pocket Edition, PDR® for Herbal Medicines™, PDR for Nutritional Supplements™, PDR® Medical Dictionary™, PDR® Nurse's Drug Handbook™, PDR® Nurse's Dictionary™, The PDR® Family Guide Encyclopedia of Medical Care™, The PDR® Family Guide to Natural Medicines and Healing Therapies™, The PDR® Family Guide to Common Ailments™, The PDR® Family Guide to Over-the-Counter Drugs™, and PDR® Electronic Library™ are trademarks used herein under license.


**Officers of Medical Economics Company:** President and Chief Executive Officer: Curtis B. Allen; Vice President, New Media: L. Suzanne BeDell; Vice President, Corporate Human Resources: Pamela M. Biliash; Chief Financial Officer: Christopher Cardik; Vice President and Controller: Barry Gray; Vice President, Finance: Donna Santarpia; Senior Vice President, Directory Services: Paul Walsh; Senior Vice President, Operations: John R. Ware

ISBN: 1-56363-330-2

While every effort has been made to reproduce products faithfully, this section is to be considered a quick reference identification aid. In cases of suspected overdosage, etc., chemical analysis of the product should be done.

**BRISTOL-MYERS SQUIBB INC.**

BRISTOL-MYERS SQUIBB ONCOLOGY P. 1034



30 units per vial  
Also available in 15 units per vial.

**Bleomycin®**  
(sterile bleomycin sulfate, USP)

BRISTOL-MYERS SQUIBB ONCOLOGY P. 1037


25 mg      50 mg

**Cytosar®**  
(cyclophosphamide tablets, USP)

BRISTOL-MYERS SQUIBB ONCOLOGY P. 1037



00 mg      200 mg      500 mg



1 g      2 g  
For injection

**Lyophilized Cytosar®**  
(cyclophosphamide for injection, USP)


BRISTOL-MYERS SQUIBB ONCOLOGY P. 1039



200 mg




300 mg



400 mg

**Droxia™**  
(hydroxyurea capsules, USP)


BRISTOL-MYERS SQUIBB ONCOLOGY P. 1041



100 mg  
Single-dose vial


**Etopophos®**  
(etoposide phosphate) for injection

RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1044



**Hex®**  
(ifosfamide for injection)

RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1047



40 mg/mL

**Megace® Oral Suspension**  
(megestrol acetate)

RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1048




20 mg

40 mg

**Megace®**  
(megestrol acetate tablets, USP)

RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1049



1-gm Multi-dose vial

**Mesnex®**  
(mesna) Injection


RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1050



40 mg

Also available in 5 mg and 20 mg  
**Mutamycin®**  
(mitomycin for injection, USP)

RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1052



50 mg

150 mg



450 mg


**Paraplatin®**  
(carboplatin for injection)

RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1055



50 mg      100 mg  
**Platinol®-AQ**  
(cisplatin injection)

RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1058



300 mg Multi-dose vial  
Also available in 30 mg,  
100 mg Multi-dose vials

**TAXOL®**  
(paclitaxel) Injection  
6 mg/mL

RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1068



100 mg  
Also available in 150 mg, 500 mg, 1 g

**VePesid®**  
(etoposide) for Injection

RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1068




50 mg

**VePesid®**  
(etoposide) Capsules

RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1070


RX BRISTOL-MYERS SQUIBB ONCOLOGY P. 1072



1 mg/mL  
200 mL

**Zerit®**  
(stavudine) for Oral Solution


C-111 BTG PHARMACEUTICALS P. 1078



2.5 mg tablets

**Oxandrin®**  
(oxandrolone tablets, USP)

RX BTG PHARMACEUTICALS P. 1078



200 mg/mL  
5 mL multiple  
dose vial

200 mg/mL  
1 mL unimatic  
single dose syringe

**Delatestryl®**  
(testosterone enanthate Injection, USP)

**CARNICK**

RX CARNICK P. 1077




**Midrin®**  
(isometheptene mucate, USP,  
dichlorophenazone, USP,  
acetaminophen, USP)  
65 mg / 100 mg / 325 mg

RX CARNICK P. 1078



15

15 mg



20 mg



30 mg



40 mg

**Zerit®**  
(stavudine) Capsules

**CELGENE**

RX CELGENE CORPORATION P. 1080



50 mg  
**THALOMID®**  
(thalidomide) Capsules

**CENTOCOR, INC.**


RX CENTOCOR, INC. P. 1080



100 mg  
Lyophilized Concentrate For IV Injection


**Remicade®**  
(infliximab recombinant)

RX CENTOCOR, INC. P. 1080



**Retavase® Full-Kit**  
(reteplase recombinant)

RX CENTOCOR, INC. P. 1080



**Retavase® Half-Kit**  
(reteplase recombinant)

**CEPHALON, INC.**

C-14 CEPHALON, INC. P. 1090


100 mg

200 mg

**Provigil®**  
(modafinil)

**CETYLITE**

RX CETYLITE INDUSTRIES INC. P. 1095



Topical Anesthetic Spray

**Cetacaine®**  
(benzocaine, butamben & tetracaine HCl)

I understand that THALOMID® (thalidomide) will be prescribed ONLY for me. I must NOT share it with ANYONE, even someone who has symptoms similar to mine. It must be kept out of the reach of children and should never be given to women who are able to have children. I have read the THALOMID® (thalidomide) patient brochure and/or viewed the videotape, "Important Information for Men and Women Taking THALOMID® (thalidomide)". I understand the contents, including other possible health problems from THALOMID® (thalidomide), so-called "side effects". I know that I cannot donate blood or semen while taking THALOMID® (thalidomide). My doctor has answered any questions I have asked.

I understand that I must participate in a survey and patient registry while I am on THALOMID® (thalidomide), which will require completing additional forms.

Information has been read aloud to me in the language of my choice. I understand that if I do not follow the doctor's instructions, I will not be able to receive THALOMID® (thalidomide). I now authorize my doctor to begin my treatment with THALOMID® (thalidomide).

Signature \_\_\_\_\_ Date \_\_\_\_\_  
(Only last six digits required) (mo./day/yr.)

Signature \_\_\_\_\_ Date \_\_\_\_\_  
(mo./day/yr.)

I explained to the patient the nature, purpose of the treatment described above, especially to women of childbearing potential. I explained to the patient if she/he has any questions regarding treatment with THALOMID® (thalidomide) have answered those questions to the best of my ability. I will ensure that the appropriate component consent form are completed. In addition, I will comply with all of my obligations and responsibilities as a prescriber registered under the restricted distribution program.

DEA No. \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_  
(mo./day/yr.)

1. 1986. Teratogenicity. Cassarett and Doull's The Basic Science of Poisons. Third Edition. New York: MacMillan Publishing Co.
2. Shaw and Newman CG. 1992. J. Med. Genet. 29:723.
3. Kaplan K, Miranda A, et al. 1993. J. Infect. Dis. 167:409-414.
4. Gran GE, Vieira LM, et al. 1991. Clin. Exp. Immunol. 84:103-108.
5. KP, Moreira AL, Sarno EN, et al. 1992. J. Exp. Med. 175:1737.
6. AC, Neubert B, Helge H, et al. 1994. Life Sci. 55:77-82.
7. Greenspan JS, Spritzler J, et al. 1997. J. Med. 336(21):1487-1493.
8. H. Smith RL, and Williams RT. 1965. Br. J. Med. 33:274-287.
9. Sengul J, Ramanujam K, et al. 1971. Bull. WHO 44:782.
10. and Conry J. 1969. Intl. J. Leprosy. 37:135-142.
11. 1971. Lep. Rev. 42:26-42.
12. data on file at Celgene.
13. 1999 CG.
14. Product Identification Guide, page 310

AGENCY telephone numbers, and the Manufacturers' Index.

## Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355

### Direct General Inquiries to:

Ph: (610) 651-6000  
(888) 874-3083  
Fax: (610) 651-6100

### Medical Emergency Contact:

Ph: 1-800-457-6399

### For Medical Information/Adverse Experience Reporting Contact:

Medical Information & Product Surveillance  
Ph: (800) 457-6399  
Fax: (610) 651-6197

## REMICADE® INFliximab recombinant For IV Injection

### DESCRIPTION

REMICADE® (infliximab) is a chimeric IgG1, monoclonal antibody with an approximate molecular weight of 149,100 daltons. It is composed of human constant and murine variable regions. Infliximab binds specifically to human tumor necrosis factor alpha (TNFα) with an association constant of  $10^{10} \text{ M}^{-1}$ . Infliximab is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses.

REMICADE is supplied as a sterile, white, lyophilized powder for intravenous infusion. Following reconstitution with 10 mL of Sterile Water for Injection, USP, the resulting pH is approximately 7.2. Each single-use vial contains 100 mg infliximab, 500 mg sucrose, 0.5 mg polysorbate 80, 2.2 mg monobasic sodium phosphate and 6.1 mg dibasic sodium phosphate. No preservatives are present.

### CLINICAL PHARMACOLOGY

#### General

Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibits binding of TNFα with its receptors.<sup>1-4</sup> Infliximab does not neutralize TNFβ (lymphotoxin α), a related cytokine that utilizes the same receptors as TNFα. Biological activities attributed to TNFα include: induction of pro-inflammatory cytokines such as IL-1 and IL-6, enhancement of leukocyte migration by increasing endothelial layer permeability and expression of adhesion molecules by endothelial cells and leukocytes, activation of neutrophil and eosinophil functional activity, induction of acute phase reactants and other liver proteins, as well as tissue degrading enzymes produced by synovocytes and/or chondrocytes. Cells expressing transmembrane TNFα bound by infliximab can be lysed *in vitro* by complement or effector cells.<sup>5</sup> Infliximab inhibits the functional activity of TNFα in a wide variety of *in vitro* bioassays utilizing human fibroblasts, endothelial cells, neutrophils,<sup>6</sup> B and T lymphocytes and epithelial cells. Anti-TNFα antibodies reduce disease activity in the cotton-top tamarin colitis model, and decrease synovitis and joint erosions in a murine model of collagen-induced arthritis. Infliximab prevents disease in transgenic mice that develop polyarthritis as a result of constitutive expression of human TNFα, and, when administered after disease onset, allows eroded joints to heal.

#### Pharmacodynamics

Elevated concentrations of TNFα have been found in the joints of rheumatoid arthritis patients<sup>7</sup> and the stools of Crohn's disease patients<sup>8</sup> and correlate with elevated disease activity. In Crohn's disease, treatment with REMICADE reduced infiltration of inflammatory cells and TNFα production in inflamed areas of the intestine, and reduced the proportion of mononuclear cells from the lamina propria able to express TNFα and interferon γ.<sup>4</sup> In rheumatoid arthritis, treatment with REMICADE reduced infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules mediating cellular adhesion (E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)), chemotaxis (interleukin 8 (IL-8) and monocyte chemoattractant protein (MCP-1)) and tissue degradation (matrix metalloproteinase (MMP) 1 and 3).<sup>4</sup> After treatment with REMICADE, patients with Crohn's disease or rheumatoid arthritis exhibited decreased levels of serum interleukin 6 (IL-6) and C-reactive protein (CRP) compared to baseline. Peripheral blood lymphocytes from REMICADE-treated patients showed no significant decrease in number or in proliferative responses to *in vitro* mitogenic stimulation when compared to cells from untreated patients.

#### Pharmacokinetics

Single intravenous infusions of 1 to 20 mg/kg showed a predictable and linear relationship between the dose administered and the maximum serum concentration and area under the concentration-time curve. The volume of distribution at steady state was independent of dose and indicated that infliximab was distributed primarily within the vascular compartment. Median pharmacokinetic results for the

recommended doses of 3 mg/kg in rheumatoid arthritis and 5 mg/kg in Crohn's disease indicate that the terminal half-life of infliximab is 8.0 to 9.5 days.

Following an initial dose of REMICADE, repeated infusions at 2 and 6 weeks in fistulizing Crohn's disease and rheumatoid arthritis patients resulted in predictable concentration-time profiles following each treatment. No systemic accumulation of infliximab occurred upon continued repeated treatment with 3 mg/kg or 10 mg/kg at 4- or 8-week intervals in rheumatoid arthritis patients or patients with moderate or severe Crohn's disease retreated with 4 infusions of 10 mg/kg REMICADE at 8-week intervals. No major differences in clearance or volume of distribution were observed in patient subgroups defined by age or weight. It is not known if there are differences in clearance or volume of distribution between gender subgroups or in patients with marked impairment of hepatic or renal function.

### CLINICAL STUDIES

#### Rheumatoid Arthritis

The safety and efficacy of REMICADE when given in conjunction with methotrexate (MTX) were assessed in a multicenter, randomized, double-blind, placebo-controlled study of 428 patients with active rheumatoid arthritis despite treatment with MTX (the Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy or ATTRACT). The median age of patients enrolled was 54 years, with a median duration of disease of 8.4 years and a median number of swollen and tender joints of 20 and 31 respectively. All patients were to have received MTX for ≥ 6 months and be on a stable dose ≥ 12.5 mg/week for 4 weeks prior to study. All REMICADE and placebo groups continued their stable dose of MTX and folic acid.

In addition to MTX, patients received placebo, 3 mg/kg or 10 mg/kg of REMICADE by intravenous infusion at weeks 0, 2 and 6 followed by additional infusions every four or eight weeks thereafter. Concurrent use of stable doses of oral corticosteroids (10 mg/day) and/or nonsteroidal anti-inflammatory drugs was also permitted. The primary endpoint was the proportion of patients at week 30 who attained an improvement in signs and symptoms as measured by the American College of Rheumatology criteria, (ACR 20). An ACR 20 response is defined as at least a 20% improvement in both tender and swollen joint counts and in 3 of the following 5 criteria: physician global assessment, patient global assessment, functional/disability measure, visual analog pain scale and erythrocyte sedimentation rate (ESR) or CRP.

At week 30, 43/86 (50%) of patients treated every 8 weeks with 3 mg/kg of REMICADE plus MTX attained an ACR 20 compared with 18/88 (20%) of patients treated with placebo plus MTX ( $p < 0.001$ ). Higher doses and/or more frequent administrations did not result in higher response rates. Results are shown in Figure 1.




Figure 1. Percentage of Patients who Achieved an ACR 20.

At week 30, the ACR 50 response was 27% for patients treated with 3 mg/kg REMICADE (infliximab) every 8 weeks plus MTX, compared to 5% for patients treated with placebo plus MTX ( $p < 0.001$ ). The ACR 70 response was 8% for patients treated with 3 mg/kg REMICADE every 8 weeks plus MTX and 0% for patients treated with placebo plus MTX. Patients receiving 3 mg/kg REMICADE every 8 weeks demonstrated superior improvement in all ACR response components except HAQ compared to patients treated with placebo plus MTX (Table 1). Data on use of REMICADE without concurrent MTX are limited (see PRECAUTIONS, Immunogenicity).<sup>1,2</sup> [See table 1 at top of next page]

#### Active Crohn's Disease

The safety and efficacy of REMICADE were assessed in a randomized, double-blind, placebo-controlled dose ranging study of 108 patients with moderate to severe active Crohn's disease<sup>9</sup> (Crohn's Disease Activity Index (CDAI)  $\geq 220 \leq 400$ ). All patients had experienced an inadequate response to prior conventional therapies, including corticosteroids (60% of patients), 5-aminosalicylates (5-ASA) (60%) and/or 6-mercaptopurine/azathioprine (6-MP/AZA) (37%). Concurrent use of stable dose regimens of corticosteroids, 5-ASA, 6-MP and/or AZA was permitted and 92% of patients continued to receive at least one of these medications. The study was divided into three phases. In the first phase, patients were randomized to receive a single intravenous

Continued on next page

## Remicade—Cont.

(IV) dose of placebo, 5, 10 or 20 mg/kg of REMICADE. The primary endpoint was the proportion of patients who experienced a clinical response, defined as a decrease in CDAI by  $\geq 70$  points from baseline at the 4-week evaluation and without an increase in Crohn's disease medications or surgery for Crohn's disease. Patients who responded at week 4 were followed to week 12. Secondary endpoints included the proportion of patients who were in clinical remission at week 4 (CDAI  $< 150$ ), and clinical response over time. At week 4, four of twenty-five (16%) of the placebo patients achieved a clinical response vs. twenty-two of twenty-seven (82%) of the patients receiving 5 mg/kg REMICADE ( $p < 0.001$ , two-sided, Fisher's Exact test). One of twenty-five (4%) placebo patients and thirteen of twenty-seven (48%) patients receiving 5 mg/kg REMICADE achieved a CDAI  $< 150$  at week 4. The maximum response to any dose of REMICADE was observed within 2 to 4 weeks. The proportion of patients responding gradually diminished over the 12 weeks of the evaluation period. There was no evidence of a dose response; doses higher than 5 mg/kg did not result in a greater proportion of responders. Results are shown in Figure 2.




Figure 2. Response ( $\geq 70$  point decrease in CDAI) to a Single IV REMICADE or Placebo Dose.

During the 12-week period following infusion, patients treated with REMICADE compared to placebo demonstrated improvement in outcomes measured by the Inflammatory Bowel Disease Questionnaire.

In the second phase, 29 patients who did not respond to the single dose of 5, 10 or 20 mg/kg of REMICADE entered the open label phase and received a single 10 mg/kg dose of REMICADE 4 weeks after the initial dose. Ten of twenty-nine (34%) patients experienced a response 4 weeks after receiving the second dose.

Patients who remained in clinical response at week 8 during the first or second phase were eligible for the retreatment phase. Seventy-three patients were re-randomized at week 12 to receive 4 infusions of placebo or 10 mg/kg REMICADE at 8-week intervals (weeks 12, 20, 28, 36) and were followed to week 48. In the limited data set available, no significant differences were observed between the REMICADE and placebo re-treated groups.

#### Fistulizing Crohn's Disease

The safety and efficacy of REMICADE were assessed in a randomized, double-blind, placebo controlled study of 94 patients with fistulizing Crohn's disease with fistula(s) that were of at least 3 months duration.<sup>10</sup> Concurrent use of stable doses of corticosteroids, 5-ASA, antibiotics, MTX, 6-MP and/or AZA was permitted, and 83% of patients continued to receive at least one of these medications. Fifty-two (55%) had multiple cutaneously draining fistulas, 90% of patients had fistula(s) in the perianal area and 10% had abdominal fistula(s).

Patients received 3 doses of placebo, 5 or 10 mg/kg REMICADE at weeks 0, 2 and 6 and were followed up to 26 weeks. The primary endpoint was the proportion of patients who experienced a clinical response, defined as  $\geq 50\%$  reduction from baseline in the number of fistula(s) draining upon gentle compression, on at least two consecutive visits, without an increase in medication or surgery for Crohn's disease.

Eight of thirty-one (26%) patients in the placebo arm achieved a clinical response vs. twenty-one of the thirty-one (68%) patients in the 5 mg/kg REMICADE arm ( $p = 0.002$ , two-sided, Fisher's Exact test). Eighteen of thirty-two (56%) patients in the 10 mg/kg arm achieved a clinical response. The median time to onset of response in the REMICADE-treated group was 2 weeks. The median duration of response was 12 weeks; after 22 weeks there was no difference between either dose of REMICADE and placebo in the proportion of patients in response (Figure 3). New fistula(s) developed in approximately 16% of both REMICADE and placebo-treated patients.

(See figure 3 in next column.)

Seven of sixty (12%) evaluable REMICADE-treated patients, compared to one of thirty-one (3.5%) placebo-treated patients, developed an abscess in the area of fistulas between 8 and 16 weeks after the last infusion of REMICADE. Six of the REMICADE patients who developed an abscess had experienced a clinical response (see ADVERSE REACTIONS, Infections).

Table 1

## MEDIAN VALUES AT BASELINE &amp; WEEK 30 FOR ACR COMPONENTS

Parameter	Placebo + MTX		3 mg/kg q 8h REMICADE +
	Baseline	30 weeks	Baseline
No. of Tender Joints	24	16	32
No. of Swollen Joints	19	13	19
Pain <sup>a</sup>	6.7	5.9	7.0
Physician's Global Assessment <sup>a</sup>	6.5	5.0	6.1
Patient's Global Assessment <sup>a</sup>	6.2	5.5	6.6
Disability Index (HAQ) <sup>b</sup>	1.8	1.5	1.8
CRP (mg/dL)	3.0	2.3	3.1
ESR (mm/hr)	39	35	40

<sup>a</sup> Visual Analog Scale (0=best, 10=worst)

<sup>b</sup> Health Assessment Questionnaire, measurement of 8 categories: dressing and grooming, arising, eating, walking, reaching, grip, and activities




Figure 3. Response (≥50% reduction in number of fistulas) with Three Doses of REMICADE (infliximab) or Placebo.

Dose regimens other than dosing at weeks 0, 2 and 6 have not been studied. Studies have not been done to assess the effects of REMICADE on healing of the internal fistular canal, on closure of non-cutaneously draining fistulas (e.g., entero-entero), or on cutaneously draining fistulas in locations other than perianal and peribdominal.

#### INDICATIONS AND USAGE

##### Rheumatoid Arthritis

REMICADE, in combination with methotrexate, is indicated for the reduction in signs and symptoms of rheumatoid arthritis in patients who have had an inadequate response to methotrexate.

##### Crohn's Disease

REMICADE is indicated for the reduction in signs and symptoms of Crohn's disease in patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.

The safety and efficacy of therapy continued beyond a single dose have not been established (see DOSAGE AND ADMINISTRATION).

REMICADE is indicated for the reduction in the number of draining enterocutaneous fistulas in patients with fistulizing Crohn's disease.

The safety and efficacy of therapy continued beyond three doses have not been studied (see DOSAGE AND ADMINISTRATION).

#### CONTRAINDICATIONS

REMICADE should not be administered to patients with known hypersensitivity to any murine proteins or other component of the product.

#### WARNINGS

##### RISK OF INFECTIONS

SERIOUS INFECTIONS, INCLUDING SEPSIS AND FATAL INFECTIONS, HAVE BEEN REPORTED IN PATIENTS RECEIVING TNF-BLOCKING AGENTS. MANY OF THE SERIOUS INFECTIONS IN PATIENTS TREATED WITH REMICADE HAVE OCCURRED IN PATIENTS ON CONCOMITANT IMMUNOSUPPRESSIVE THERAPY THAT, IN ADDITION TO THEIR CROHN'S DISEASE OR RHEUMATOID ARTHRITIS, COULD PREDISPOSE THEM TO INFECTIONS. CAUTION SHOULD BE EXERCISED WHEN CONSIDERING THE USE OF REMICADE IN PATIENTS WITH A CHRONIC INFECTION OR A HISTORY OF RECURRENT INFECTION. REMICADE SHOULD NOT BE GIVEN TO PATIENTS WITH A CLINICALLY IMPORTANT, ACTIVE INFECTION. PATIENTS WHO DEVELOP A NEW INFECTION WHILE UNDERGOING TREATMENT WITH REMICADE SHOULD BE MONITORED CLOSELY. IF A PATIENT DEVELOPS A SERIOUS INFECTION OR SEPSIS, REMICADE THERAPY SHOULD BE DISCONTINUED (see ADVERSE REACTIONS, Infections).

##### Hypersensitivity

REMICADE has been associated with hypersensitivity reactions that vary in their time of onset. Most hypersensitivity reactions, which include urticaria, dyspnea, and/or hypotension, have occurred during or within 2 hours of infliximab infusion. However, in some cases, serum sickness-like reactions have been observed in Crohn's disease patients 3 to 12 days after REMICADE therapy was reinstituted following an extended period without REMICADE treatment. Symptoms associated with these reactions include fever, rash, headache, sore throat, myalgias, polyarthralgias, hand and facial edema and/or dysphagia. These reactions were associated with marked increase in antibodies to infliximab, loss of detectable serum concentrations of REMICADE, and possible loss of drug efficacy. REMICADE

should be discontinued for severe reactions. In the treatment of hypersensitivity reactions (e.g., phen, antihistamines, corticosteroids and/or epinephrine should be available for immediate use in the event of an anaphylactic reaction (see ADVERSE REACTIONS, Infusion-related reactions).

#### PRECAUTIONS

##### Autoimmunity

Treatment with REMICADE may result in the development of autoantibodies and, rarely, in the development of a syndrome resembling systemic lupus erythematosus. If a patient develops symptoms of a lupus-like syndrome following treatment with REMICADE, treatment should be discontinued (see ADVERSE REACTIONS, Autoantibodies/Lupus-like Syndrome).

##### Malignancy

Patients with long duration of Crohn's disease, rheumatoid arthritis and chronic exposure to immunosuppressive therapies are more prone to develop lymphoproliferative disorders (see ADVERSE REACTIONS, Malignancies/Lymphoproliferative Disorders). The impact of treatment with REMICADE on these phenomena is unknown.

##### Immunogenicity

Treatment with REMICADE can be associated with development of antibodies to infliximab (also referred to as anti-infliximab antibodies, HACA). One hundred four of the 199 Crohn's disease patients treated with REMICADE were evaluated for the development of specific antibodies; 18 (13%) were antibody positive at low titer,  $< 1:20$ . Patients who were antibody positive were more likely to experience an infusion-related reaction (see ADVERSE REACTIONS, Infusion-related reactions). Antibody development was lower among rheumatoid arthritis and Crohn's disease patients receiving immunosuppressive therapies such as 6-MP, AZA or MTX. With dosing of REMICADE, serum concentrations of infliximab were higher in rheumatoid arthritis patients than in Crohn's disease patients. There are limited data available on the development of antibodies to infliximab in patients receiving long-term treatment with REMICADE. Because immunogenicity analyses are product-specific, comparison of antibody rates to those from other products is not appropriate.

##### Vaccinations

No data are available on the response to vaccination in patients receiving anti-TNF therapy. It is recommended that live vaccines not be given concurrently.

##### Drug Interactions

Specific drug interaction studies, including studies with MTX, have not been conducted. The majority of patients in rheumatoid arthritis or Crohn's disease studies received one or more concomitant medications. Concomitant medications included nonsteroidal anti-inflammatory agents, corticosteroids and/or narcotics. Concomitant Crohn's disease medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates. Patients with Crohn's disease who received immunosuppressants tended to experience fewer infusion reactions compared to patients who did not receive immunosuppressants (see PRECAUTIONS, Immunogenicity and ADVERSE REACTIONS, Infusion-related reactions).

##### Carcinogenesis, Mutagenesis and Impairment of Fertility

Long-term studies in animals have not been performed to evaluate the carcinogenic potential. No clastogenic or genotoxic effects of infliximab were observed in the mouse micronucleus test or the *Salmonella*-E. coli (Ames) assay, respectively. Chromosomal aberrations were not observed in an assay performed using human lymphocytes. It is not known whether infliximab can impair fertility in humans. No impairment of fertility was observed in a general reproduction toxicity study conducted in mice using an analogous antibody that selectively binds to the functional activity of mouse TNF $\alpha$ .

##### Pregnancy Category C

Since infliximab does not cross-react with TNF $\alpha$  in other than humans and chimpanzees, animal reproduction studies have not been conducted with REMICADE. It is not known whether REMICADE can cause harm when administered to a pregnant woman or can affect reproduction capacity while infliximab is present in the serum (see CLINICAL PHARMACOLOGY, Pharmacokinetics). REMICADE should be given to a pregnant woman if clearly needed. No evidence of maternal toxicity, toxicity or teratogenicity was observed in a developmental

study conducted in mice using an analogous anti-TNF $\alpha$  that selectively inhibits the functional activity of TNF $\alpha$ .

#### Infusion-Related Reactions

It is not known whether infliximab is excreted in human milk or absorbed systemically after ingestion. Because drugs and immunoglobulins are excreted in human milk, and because of the potential for adverse reactions in nursing infants from REMICADE, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

#### Pediatric Use

The safety and effectiveness of REMICADE in patients with juvenile rheumatoid arthritis and in pediatric patients with Crohn's disease have not been established.

#### Geriatric Use

The ATTRACT study, no overall differences were observed in effectiveness or safety in the 72 patients aged 65 or older compared to younger patients. In Crohn's disease studies, there were insufficient numbers of patients aged 65 or older to determine whether they respond differently from patients aged 18 to 65. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly (see ADVERSE REACTIONS, Infections).

#### ADVERSE REACTIONS

Of 771 patients were treated with REMICADE in clinical trials. In both rheumatoid arthritis and Crohn's disease trials, approximately 5% of patients discontinued REMICADE because of adverse experiences. The most common reasons for discontinuation of treatment were dyspnea, nausea, and headache.

#### Infusion-related Reactions

##### Infusion reactions

An infusion reaction was defined as any adverse event occurring during the infusion or within 1 to 2 hours after the infusion. Seventeen percent of REMICADE-treated patients in clinical trials experienced an infusion reaction compared to 7% of placebo-treated patients. Among the 3284 REMICADE infusions, 4% were accompanied by nonspecific symptoms such as fever or chills, 1% were accompanied by rash or urticaria, 1% were accompanied by cardiopulmonary reactions (primarily chest pain, hypotension, hyperoxia or dyspnea), and 0.1% were accompanied by common symptoms of pruritus/urticaria and cardiopulmonary reactions. Less than 2% of patients discontinued REMICADE because of infusion reactions, and all patients recovered with treatment and/or discontinuation of infusion. REMICADE infusions beyond the initial infusion in rheumatoid arthritis patients were not associated with a higher rate of reactions.

Patients with Crohn's disease who became positive for antibodies to infliximab were more likely to develop infusion reactions than were those who were negative (36% vs. 11% respectively). Use of concomitant immunosuppressant drugs appeared to reduce the frequency of antibodies to infliximab and infusion reactions (see PRECAUTIONS, Immunogenicity and Drug Interactions).

##### Reactions following readministration

In a clinical trial of forty patients with Crohn's disease readministered with infliximab following a 2 to 4 year period without infliximab treatment, 10 patients experienced adverse reactions manifesting 3 to 12 days following infusion of which were considered serious. Signs and symptoms included fever and/or arthralgia with fever and/or rash, with some patients also experiencing pruritus, facial, hand or lip swelling, dysphagia, urticaria, sore throat, and headache. Patients experiencing these adverse events had not experienced infusion-related adverse events associated with their initial infliximab therapy. Of the 40 patients enrolled, these events occurred in 9 of 23 (39%) who had received intravenous formulation which is no longer in use and 1 of 17 (6%) who received lyophilized formulation. The clinical data are inadequate to determine if occurrence of these reactions is due to differences in formulation. Patients' signs and symptoms improved substantially or resolved with treatment in most cases. There are insufficient data on the incidence of events after drug-free intervals of less than 2 years. However, these events have been observed infrequently in clinical trials and post-marketing surveillance at intervals greater than 1 year.

REMICADE clinical trials, infections were reported by REMICADE-treated patients (average of 27 weeks of follow-up) and by 16% of placebo-treated patients (average of 27 weeks of follow-up). The infections most frequently reported were upper respiratory tract infections (including, sinusitis, pharyngitis, and bronchitis) and urinary tract infections. No increased risk of serious infections or sepsis has been observed with Remicade compared to placebo. Among REMICADE-treated patients, these serious infections included pneumonia, cellulitis, pyelonephritis and sepsis. In the ATTRACT study, one patient died with disseminated tuberculosis and one died with disseminated coccidioidomycosis. The relationship to REMICADE is unknown (see WARNINGS, Risk of Infections). Twelve percent of patients receiving Crohn's disease developed a new abscess 8 weeks after the last infusion of REMICADE (see CLINICAL STUDIES, Fistulizing Crohn's Disease).

##### Antibodies/Lupus-like Syndrome

Patients were tested for autoantibodies at multiple time points. In the rheumatoid arthritis ATTRACT study, 23% of

Table 2

#### ADVERSE EVENTS IN RHEUMATOID ARTHRITIS AND CROHN'S DISEASE TRIALS

	RHEUMATOID ARTHRITIS		CROHN'S DISEASE	
	Placebo (n=133)	REMICADE (infliximab) (n=555)	Placebo (n=56)	REMICADE (n=199)
Avg. weeks of follow-up	22.3	26.9	14.7	27.0
Respiratory				
Upper respiratory infection	13%	20%	9%	16%
Coughing	5%	10%	0%	5%
Sinusitis	3%	9%	2%	5%
Rhinitis	4%	8%	4%	6%
Pharyngitis	5%	8%	5%	9%
Bronchitis	2%	4%	2%	7%
Gastrointestinal				
Nausea	17%	14%	4%	17%
Abdominal Pain	7%	8%	4%	12%
Vomiting	10%	5%	0%	9%
Other				
Headache	10%	20%	21%	23%
Rash	4%	9%	5%	6%
Fatigue	5%	6%	5%	11%
Fever	4%	6%	7%	10%
Back pain	2%	6%	4%	5%
Pain	4%	6%	5%	9%
Urinary tract infection	3%	6%	4%	3%
Pruritus	0%	5%	2%	5%
Moniliasis	2%	3%	0%	5%

REMICADE-treated patients developed antinuclear antibodies (ANA) between screening and last evaluation, compared to 6% of placebo-treated patients. Anti-dsDNA antibodies developed in approximately 4% of REMICADE-treated patients, compared to none of the placebo-treated patients. No association was seen between REMICADE dose/schedule and development of ANA or anti-dsDNA. Of Crohn's disease patients treated with REMICADE who were evaluated for antinuclear antibodies (ANA), 34% developed ANA between screening and last evaluation. Anti-dsDNA antibodies developed in approximately 9% of Crohn's disease patients treated with REMICADE. The development of anti-dsDNA antibodies was not related to either the dose or duration of REMICADE treatment. However, baseline therapy with an immunosuppressant in Crohn's disease patients was associated with reduced development of anti-dsDNA antibodies (3% compared to 21% in patients not receiving any immunosuppressant). Crohn's disease patients were approximately 2 times more likely to develop anti-dsDNA antibodies if they were ANA-positive at study entry.

Three patients developed clinical symptoms consistent with a lupus-like syndrome, two with rheumatoid arthritis and one with Crohn's disease. All three patients improved following discontinuation of therapy and appropriate medical treatment (see PRECAUTIONS, Autoimmunity).

#### Malignancies/Lymphoproliferative Disease

Five new and 2 recurrent malignancies were observed in 6 of 771 patients treated with REMICADE for up to 36 weeks in clinical trials. These were non-Hodgkin's B-cell lymphoma, breast cancer, melanoma, squamous cell cancer of the skin, and basal cell cancer. There are insufficient data to determine whether Remicade contributed to the development of these malignancies. The observed rates and incidences were similar to those expected for the populations studied<sup>12,13</sup> (see PRECAUTIONS, Malignancy).

#### Other Adverse Reactions

Adverse events occurring at a frequency of at least 5% in trials in patients with rheumatoid arthritis or Crohn's disease are shown in Table 2. Patients with Crohn's disease who were treated with REMICADE were more likely than patients with rheumatoid arthritis to experience adverse events associated with gastrointestinal symptoms.

(See Table 2 above)

Serious adverse events by body system that occurred in all patients treated with REMICADE at frequencies <2% are as follows:

**Body as a whole:** abdominal hernia, chest pain, fall, pain  
**Blood:** splenic infarction, splenomegaly  
**Cardiovascular:** hypertension, hypotension, syncope  
**Central & Peripheral Nervous:** dizziness, headache, upper motor neuron lesion  
**Collagen:** lupus erythematosus syndrome, rheumatoid nodules  
**Ear and Hearing:** ceruminosis  
**Gastrointestinal:** abdominal pain, Crohn's disease, diarrhea, gastric ulcer, intestinal obstruction, intestinal perforation, intestinal stenosis, nausea, pancreatitis, proctalgia, vomiting  
**Heart Rate and Rhythm:** palpitation, tachycardia  
**Liver and Biliary:** cholecystitis  
**Metabolic and Nutritional:** dehydration, pancreatic insufficiency, weight decrease  
**Musculoskeletal:** arthropathy, back pain, bone fracture, myalgia, tendon disorder, tendon injury  
**Myo., Endo., Pericardial and Coronary Value:** cardiac failure, myocardial ischemia  
**Neoplasms:** lymphoma  
**Platelet, Bleeding and Clotting:** thrombocytopenia  
**Psychiatric:** anxiety, confusion, delirium, depression, somnolence, suicide attempt  
**Red Blood Cell:** anemia  
**Resistance Mechanism:** abscess, cellulitis, fever, infection bacterial, sepsis

**Respiratory:** adult respiratory distress syndrome, bronchitis, coughing, dyspnea, pleurisy, pneumonia, pulmonary infiltration, respiratory insufficiency  
**Skin and Appendages:** furunculosis, rash, increased sweating

**Urinary:** azotemia, dysuria, hydronephrosis, kidney infarction, renal failure, ureteral obstruction  
**Vascular (Extracardiac):** brain infarction, pulmonary embolism, thrombophlebitis deep

**White cell and Reticuloendothelial:** leukopenia, lymphadenopathy

A greater proportion of patients enrolled into the ATTRACT trial who received REMICADE plus MTX experienced mild, transient elevations (<2 times the upper limit of normal) in AST or ALT (37% each) compared to patients treated with placebo plus MTX (AST: 24%, ALT: 29%). Five (1.5%) patients treated with REMICADE and MTX experienced more prolonged elevations in their ALT.

#### OVERDOSAGE

Single doses up to 20 mg/kg have been administered without any direct toxic effect. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately.

#### DOSAGE AND ADMINISTRATION

##### Rheumatoid Arthritis

The recommended dose of REMICADE is 3 mg/kg given as an intravenous infusion followed with additional 3 mg/kg doses at 2 and 6 weeks after the first infusion then every 8 weeks thereafter. Remicade should be given in combination with methotrexate.

##### Crohn's Disease

The recommended dose of REMICADE is 5 mg/kg given as a single intravenous infusion for treatment of moderately to severely active Crohn's disease. In patients with fistulizing disease, an initial 5 mg/kg dose should be followed with additional 5 mg/kg doses at 2 and 6 weeks after the first infusion.

There are insufficient safety and efficacy data for the use of REMICADE in Crohn's disease beyond the recommended duration (see WARNINGS, Hypersensitivity; ADVERSE REACTIONS, Infusion-related Reactions; and INDICATIONS AND USAGE).

**Preparation and administration instructions:** Use aseptic technique.

REMICADE vials do not contain antibacterial preservatives. Therefore, the vials after reconstitution should be used immediately, not re-entered or stored. The diluent to be used for reconstitution is 10 mL of Sterile Water for Injection, USP. The total dose of the reconstituted product must be further diluted to 250 mL with 0.9% Sodium Chloride Injection, USP. The infusion concentration should range between 0.4 mg/mL and 4 mg/mL. The REMICADE infusion should begin within 3 hours of preparation.

1. Calculate the dose and the number of REMICADE vials needed. Each REMICADE vial contains 100 mg of infliximab. Calculate the total volume of reconstituted REMICADE solution required.

2. Reconstitute each REMICADE vial with 10 mL of Sterile Water for Injection, USP, using a syringe equipped with a 21-gauge or smaller needle. Remove the flip-top from the vial and wipe the top with an alcohol swab. Insert the syringe needle into the vial through the center of the rubber stopper and direct the stream of Sterile Water for Injection, USP, to the glass wall of the vial. Do not use the vial if the vacuum is not present. Gently swirl the solution by rotating the vial to dissolve the lyophilized powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE. Foaming of the solution on reconstitution is not unusual. Allow the reconstituted solution to stand for 5 minutes. The solution should be colorless to light yellow.

Continued on next page

## Remicade—Cont.

and opalescent, and the solution may develop a few translucent particles as infliximab is a protein. Do not use if opaque particles, discoloration, or other foreign particles are present.

3. Dilute the total volume of the reconstituted REMICADE solution dose to 250 mL with 0.9% Sodium Chloride Injection, USP, by withdrawing a volume of 0.9% Sodium Chloride Injection, USP, equal to the volume of reconstituted REMICADE from the 0.9% Sodium Chloride Injection, USP, 250 mL bottle or bag. Slowly add the total volume of reconstituted REMICADE solution to the 250 mL infusion bottle or bag. Gently mix.
4. The infusion solution must be administered over a period of not less than 2 hours and must use an infusion set with an in-line, sterile, non-pyrogenic, low-protein-binding filter (pore size of 1.2-µm or less). Any unused portion of the infusion solution should not be stored for reuse.
5. No physical biochemical compatibility studies have been conducted to evaluate the co-administration of REMICADE with other agents. REMICADE should not be infused concomitantly in the same intravenous line with other agents.
6. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If visibly opaque particles, discoloration or other foreign particulates are observed, the solution should not be used.

## Storage

Store the lyophilized product under refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not use beyond the expiration date. This product contains no preservative.

## HOW SUPPLIED

REMICADE (infliximab) lyophilized concentrate for IV injection is supplied in individually-boxed single-use vials in the following strength:

NDC 57894-030-01 100 mg infliximab in a 20-mL vial

## REFERENCES

1. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McCann M, Scallan B, Moore MA, Vilcek J, Daddona P, Ghayab J. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. *Molec Immunol* 1993;30:1443-1453.
2. Scallan BJ, Moore MA, Trinh H, Knight DM, Ghayab J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNFα and activates immune effector functions. *Cytokine* 1995;7:251-259.
3. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, Kollas G, Ghayab J, Vilcek J, Daddona PE. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF *in vitro* and protects transgenic mice from cachexia and TNF lethality *in vivo*. *Cytokine* 1995;7:15-25.
4. Data on file.
5. Chu CQ, Field M, Feldmann M and Maini RN. Localization of tumor necrosis factor, alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. *Arthritis and Rheum* 1991;34:1125-1132.
6. Braeuer CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. *Lancet* 1992;339:89-91.
7. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis Rheum* 1998;41(9):1552-1563.
8. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. *Lancet* 1994 Oct 22;344(8930):1105-1110.
9. Targan SR, Hanauer SR, van Deventer SJH, Mayer L, Present D, Braakman T, DeWoody K, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. *N Engl J Med* 1997;337(15):1029-1035.
10. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogerand RA, Podolsky DK, Sands B, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH. Infliximab for the treatment of fistulas in patients with Crohn's disease. *N Engl J Med* 1999;340:1398-1405.
11. Greenstein AJ, Mullin GE, Strauchen JA, Heimann T, et al. Lymphoma in inflammatory bowel disease. *Cancer* 1992;69:1119-21.
12. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. *Br J Rheum* 1996;35:738-45.

Centocor, Inc., Malvern, PA 19355, USA License #1242  
1-800-457-6399 9 November 1999

Shown in Product Identification Guide, page 310.

## RETAVERSE®

Reteplase,  
recombinant

## DESCRIPTION

Retavase® (Reteplase) is a non-glycosylated deletion mutant of tissue plasminogen activator (tPA), containing

the kringle 2 and the protease domains of human tPA. Retavase® contains 355 of the 527 amino acids of native tPA (amino acids 1-3 and 176-527). Retavase® is produced by recombinant DNA technology in *E. coli*. The protein is isolated as inactive inclusion bodies from *E. coli*, converted into its active form by an *in vitro* folding process and purified by chromatographic separation. The molecular weight of Reteplase is 39,571 daltons.

Potency is expressed in units (U) using a reference standard which is specific for Reteplase® and is not comparable with units used for other thrombolytic agents.

Retavase® is a sterile, white, lyophilized powder for intravenous bolus injection after reconstitution with Sterile Water for Injection, USP (without preservatives). Following reconstitution, the pH is 6.0 ± 0.3. Retavase® is supplied as a 10.4 U vial to ensure sufficient drug for administration of each 10 U dose. Each single-use vial contains:

## 10.4 U (18.1 mg) Vial

Reteplase	18.1 mg
Tranexamic Acid	8.32 mg
Dipotassium Hydrogen Phosphate	136.24 mg
Phosphoric Acid	51.27 mg
Sucrose	364.0 mg
Polysorbate 80	5.20 mg

## CLINICAL PHARMACOLOGY

## General

Retavase® is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.<sup>1,2</sup> In a controlled trial, 36 of 56 patients treated for an acute myocardial infarction (AMI) had a decrease in fibrinogen levels to below 100 mg/dL by 2 hours following the administration of Retavase® as a double-bolus intravenous injection (10 + 10 U) in which 10 U (17.4 mg) was followed 30 minutes later by a second bolus of 10 U (17.4 mg).<sup>3</sup> The mean fibrinogen level returned to the baseline value by 48 hours.

## Pharmacokinetics

Based on the measurement of thrombolytic activity, Retavase® is cleared from plasma at a rate of 250-450 mL/min, with an effective half-life of 13-16 minutes. Retavase® is cleared primarily by the liver and kidney.

## Clinical Studies

The safety and efficacy of Retavase® were evaluated in three controlled clinical trials in which Retavase® was compared to other thrombolytic agents. The INJECT study was designed to assess the relative effects of Retavase® or the Streptokinase brand of Streptokinase upon mortality rates at 35 days following an AMI. The other studies (RAPID 1 and RAPID 2) were arteriographic studies which compared the effect on coronary patency of Retavase® to two regimens of Alteplase (a tissue plasminogen activator; Activase® in the USA and Actilyse® in Europe) in patients with an AMI. In all three studies, patients were treated with aspirin (initial doses of 160 mg to 350 mg and subsequent doses of 75 mg to 350 mg) and heparin (a 5,000 U IV bolus prior to the administration of Retavase®, followed by a 1000 U/hour continuous IV infusion for at least 24 hours).<sup>4,5</sup> The safety and efficacy of Retavase® have not been evaluated using anti-thrombotic or antiplatelet regimens other than those described above.

Retavase® (10 + 10 U) was compared to Streptokinase (1.5 million units over 60 minutes) in a double-blind, randomized, European study (INJECT), which studied 6,010 patients treated within 12 hours of the onset of symptoms of AMI. To be eligible for enrollment, patients had to have chest pain consistent with coronary ischemia and ST segment elevation, or a bundle branch block pattern on the EKG. Patients with known cerebrovascular or other bleeding risks or those with a systolic blood pressure >200 mm Hg or a diastolic blood pressure >100 mm Hg were excluded from enrollment. The results of the primary endpoint (mortality at 35 days), six month mortality and selected other 35 day endpoints are shown in Table 1 for patients receiving study medications.

(See table 1 below)

Table 1  
INJECT TRIAL  
Incidence of Selected Outcomes

Endpoint	Retavase® n = 2,965	Streptokinase n = 2,971	Retavase®-Streptokinase difference (95% CI)
35 Day mortality	8.9%	9.4%	-0.5 (-2.0, 0.9)
6 Month mortality <sup>1</sup>	11.0%	12.1%	-1.1 (-2.7, 0.6)
Combined outcome of 35 day mortality or nonfatal stroke within 35 days	9.6%	10.2%	-0.6 (-2.1, 1.0)
Heart failure	24.8%	28.1%	-3.3 (-5.6, -1.1)
Cardiogenic shock	4.6%	5.8%	-1.2 (-2.4, -0.1)
Any stroke	1.4%	1.1%	0.3 (-0.3, 0.8)
Intracranial hemorrhage	0.8%	0.4%	0.4 (0.0, 0.8)

<sup>1</sup>p value for the exploratory analysis comparing Retavase® versus Streptokinase.

<sup>2</sup>Kaplan-Meier estimates.

For mortality, stroke and the combined outcome of mortality or stroke, the 95% confidence intervals in Table 1 fall within the range within which the true difference in outcomes lies and includes the possibility of no difference. The incidences of congestive heart failure and of cardiogenic shock were significantly lower among patients treated with Retavase®.

The total incidence of stroke was similar between the two groups. However, more patients treated with Retavase® experienced hemorrhagic strokes than patients treated with Streptokinase. An exploratory analysis indicates the incidence of intracranial hemorrhage was higher in older patients or those with elevated blood pressure. The incidence of intracranial hemorrhage among the patients treated with Retavase® who were older than 70 years was 2.2%. Intracranial hemorrhage occurred in 0.8% (2.4%) patients treated with Retavase® who had a systolic blood pressure >160 mm Hg and in 1.5% (0.6%) Retavase® patients who had an initial systolic blood pressure <160 mm Hg.

Two arteriographic studies (RAPID 1 and RAPID 2) performed utilizing open-label administration of Retavase® and a blinded review of the arteriograms. In RAPID 1, patients were treated within 6 hours of the onset of symptoms, and in RAPID 2, patients were treated 12 hours of the onset of symptoms. Both studies compared coronary artery perfusion through the infarct-related artery 90 minutes after the initiation of therapy as the endpoint. Some patients in each study also had a second arteriogram at 30 minutes after the initiation of therapy. In RAPID 1, Retavase® doses of 10 + 10 U, 15 U, or 10 + 5 U were compared to a 3-hour regimen of Alteplase (100 mg administered over 3 hours). In RAPID 2, Retavase® (10 + 10 U) was compared to an accelerated regimen of Alteplase (100 mg administered over 1.5 hrs). The percentages of patients with complete flow (TIMI grades 2 or 3) and complete flow (TIMI grade 3), are shown along with ventricular function measurements in Table 2. The follow-up arteriogram was performed at a median of 8 (RAPID 1) and 5 (RAPID 2) days after the administration of the thrombolytics. In RAPID 1, the best patency results were obtained with the 10 + 10 U dose. In RAPID 2, the percentage of patients with complete flow and the percentage of patients with complete flow was significantly higher with Retavase® than with Alteplase at 90 minutes after the initiation of therapy. In both clinical trials the reocclusion rates were similar. Retavase® and Alteplase. The relationship between coronary artery patency and clinical efficacy has not been established.

(See table 2 at bottom of next page)

Approximately 70% (RAPID 1) and 78% (RAPID 2) patients in the arteriographic studies underwent a second arteriography at 60 minutes following the administration of the study agents. In both trials the percentage of patients with complete flow at 60 minutes was significantly higher with Retavase® than with Alteplase. Neither trial was designed nor powered to compare the safety or efficacy of Retavase® and Alteplase with respect to outcomes of mortality and stroke.

## INDICATIONS AND USAGE

Retavase® (Reteplase) is indicated for use in the treatment of acute myocardial infarction (AMI) to improve ventricular function following AMI, to reduce the incidence of congestive heart failure, and to reduce the mortality associated with AMI. Retavase® should be initiated as soon as possible after the onset of symptoms (see CLINICAL PHARMACOLOGY).

## CONTRAINDICATIONS

Because thrombolytic therapy increases the risk of bleeding, Retavase® is contraindicated in the following situations:

- Active internal bleeding
- History of cerebrovascular accident
- Recent intracranial or intraspinal surgery or trauma

## WARNINGS



Table 1  
Adverse Events  $\geq 5\%$  of Patients (N=315)

Adverse Event	N	Incidence All Grades	%
All	275		87
Whole	154		49
Headache	102		32
Fatigue	49		16
Joint Pain	43		14
Joint Irritation	19		6
Joint Pain	18		6
Respiratory System	32		10
Cardiovascular System	55		18
Neurological System	23		7
Endocrine and Lymphatic System	33		11
Neutropenia	25		8
Thrombocytopenia	21		7
Diarrhea and Nutritional System	41		13
Edema	21		7
Skeletal System	23		7
Genitourinary System	25		8
Neuropathy	24		8
Appendages	32		10
Other	31		10
Unknown	24		8

and pulmonary symptoms and culminated in death several days following the last RITUXAN infusion. The cause of death was not known.

The following adverse events were reported in patients with pneumonitis or bronchiolitis obliterans: cough, dyspnea, bronchitis, and chest pain. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with hypertension: headache, dizziness, and chest pain. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with diabetes: hyperglycemia, hypoglycemia, and weight gain. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with rheumatoid arthritis: joint pain, joint swelling, and joint stiffness. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with multiple sclerosis: optic neuritis and uveitis. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with systemic lupus erythematosus: skin rash, joint pain, and fatigue. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with Sjögren's syndrome: dry mouth, dry eyes, and dry skin. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with Crohn's disease: abdominal pain, diarrhea, and weight loss. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with ulcerative colitis: abdominal pain, diarrhea, and weight loss. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with psoriasis: skin rash, joint pain, and fatigue. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with vitiligo: skin rash, joint pain, and fatigue. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with alopecia: skin rash, joint pain, and fatigue. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

The following adverse events were reported in patients with tinnitus: skin rash, joint pain, and fatigue. The incidence of these events was higher in patients with lesions  $>10$  cm than in patients with lesions  $<10$  cm.

and dilute to a final concentration of 1 to 4 mg/mL into an infusion bag containing either 0.9% Sodium Chloride, USP, or 5% Dextrose in Water, USP. Gently invert the bag to mix the solution. Discard any unused portion left in the vial. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

RITUXAN solutions for infusion are stable at 2–8°C (36–46°F) for 24 hours and at room temperature for an additional 12 hours. No incompatibilities between RITUXAN and polyvinylchloride or polyethylene bags have been observed.

**Administration:** DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS. Hypersensitivity reactions may occur (see WARNINGS). Premedication consisting of acetaminophen and diphenhydramine should be considered before each infusion of RITUXAN. Premedication may attenuate infusion-related events. Since transient hypotension may occur during RITUXAN infusion, consideration should be given to withholding antihypertensive medications 12 hours prior to RITUXAN infusion.

**First Infusion:** The RITUXAN solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. RITUXAN should not be mixed or diluted with other drugs. If hypersensitivity or infusion-related events do not occur, escalate the infusion rate in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr. If hypersensitivity or an infusion-related event develops, the infusion should be temporarily slowed or interrupted (see WARNINGS). The infusion can continue at one-half the previous rate upon improvement of patient symptoms.

**Subsequent Infusions:** Subsequent RITUXAN infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.

**Stability and Storage:** RITUXAN vials are stable at 2–8°C (36–46°F). Do not use beyond expiration date stamped on carton. RITUXAN vials should be protected from direct sunlight.

#### HOW SUPPLIED

RITUXAN is supplied as 100 mg and 500 mg of sterile, preservative-free, single-use vials.

Single unit 100 mg carton: Contains one 10 mL vial of RITUXAN (10 mg/mL).

NDC 50242-051-21

Single unit 500 mg carton: Contains one 50 mL vial of RITUXAN (10 mg/mL).

NDC 50242-053-06

#### REFERENCES

- Valentine MA, Meier KE, Rossie S, et al. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. *J Biol Chem* 1989 264(19):11282–11287.
- Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. *EMBO J* 1988 7(3):711–717.
- Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. *Blood* 1984 63(6):1424–1433.
- Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. *J Immunol* 1985 135(2):973–979.

- Tedder TF, Zhou LJ, Bell PD, et al. The CD20 surface molecule of B lymphocytes functions as a calcium channel. *J Cell Biochem* 1990 14D:195.
- Press OW, Applebaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. *Blood* 1987 69(2):584–591.
- Reff ME, Carner C, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. *Blood* 1994 83(2):435–445.
- Demidem A, Lam T, Alas S, Hariharan K, Hanna N, and Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. *Cancer Biotherapy & Radiopharmaceuticals* 1997 12(3):177–186.
- Maloney DG, Liles TM, Czerwinski C, Waldichuk J, Rosenberg J, Grillo-López A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. *Blood* 1994 84(8):2457–2466.
- Maloney DG, Grillo-López AJ, Bodkin D, White CA, Liles T-M, Royston I, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. *J Clin Oncol* 1997 15(10):3266–3274.
- Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schluder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. *Blood* 1997 90(6):2188–2195.

#### Jointly Marketed by:

IDEC Pharmaceuticals Corporation  
3030 Callan Road  
San Diego, CA 92121  
7202000 LJ0070  
Genentech, Inc.  
1 DNA Way  
South San Francisco, CA 94080-4990  
(480)703 Revised July 1999

© 1999 IDEC Pharmaceuticals Corporation and Genentech, Inc.  
Shown in Product Identification Guide, page 318

#### Immunex Corporation

51 UNIVERSITY STREET  
SEATTLE, WA 98101

#### For Medical Information Contact:

**Generally:**  
Professional Services  
(800) 466-8639  
FAX: (800) 221-6820  
FAX: (206) 223-5525  
**In Emergencies:**  
Professional Services  
(800) 466-8639  
FAX: (800) 221-6820  
FAX: (206) 223-5525

**ENBREL®**  
[en-brel]  
(etanercept)

#### DESCRIPTION

ENBREL (etanercept) is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the C<sub>2</sub> domain, the C<sub>3</sub> domain and hinge region, but not the C<sub>H1</sub> domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons.

ENBREL is supplied as a sterile, white, preservative-free, lyophilized powder for parenteral administration after reconstitution with 1 mL of the supplied Sterile Bacteriostatic Water for Injection, USP (containing 0.9% benzyl alcohol). Following reconstitution, the solution of ENBREL is clear and colorless, with a pH of 7.4 ± 0.3. Each single-use vial of ENBREL contains 25 mg etanercept, 40 mg mannitol, 10 mg sucrose, and 1.2 mg tromethamine.

#### CLINICAL PHARMACOLOGY

##### General

Etanercept binds specifically to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors. TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It plays an important role in the inflammatory processes of rheumatoid arthritis (RA), polyarticular-course juvenile rheumatoid arthritis (JRA), and the resulting joint pathology.<sup>1,2</sup> Elevated levels of TNF are found in the synovial fluid of RA patients.<sup>3</sup> Two distinct receptors for TNF (TNFR<sub>1</sub>), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75), exist natu-

Continued on next page



## Enbrel—Cont.

rally as monomeric molecules on cell surfaces and in soluble forms.<sup>4</sup> Biological activity of TNF is dependent upon binding to either cell surface TNFR.

Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules. It inhibits the activity of TNF in vitro and has been shown to affect several animal models of inflammation, including murine collagen-induced arthritis.<sup>5,6</sup> Etanercept inhibits binding of both TNF $\alpha$  and TNF $\beta$  (lymphotoxin  $\alpha$  [LT $\alpha$ ]) to cell surface TNFRs, rendering TNF biologically inactive.<sup>6</sup> Cells expressing transmembrane TNF that bind ENBREL are not lysed in vitro in the presence or absence of complement.<sup>6</sup>

Etanercept can also modulate biological responses that are induced or regulated by TNF, including expression of adhesion molecules responsible for leukocyte migration (i.e., E-selectin and to a lesser extent intercellular adhesion molecule-1 [ICAM-1]), serum levels of cytokines (e.g., IL-6), and serum levels of matrix metalloproteinase-3 (MMP-3 or stromelysin).<sup>6</sup>

## Pharmacokinetics

After administration of 25 mg of ENBREL by a single subcutaneous (SC) injection to three patients with RA, a median half-life of 115 hours (range 98 to 300 hours) was observed with a clearance of 89 mL/hr (52 mL/hr/m<sup>2</sup>). A maximum serum concentration (C<sub>max</sub>) of 1.2 mcg/mL (range 0.6 to 1.5 mcg/mL) and time to C<sub>max</sub> of 72 hours (range 48 to 96 hours) was observed in these patients. After continued dosing of RA patients (N=25) with ENBREL for 6 months with 25 mg twice weekly, the median observed level was 3.0 mcg/mL (range 1.7 to 5.6 mcg/mL). Based on the available data, individual patients may undergo a two- to five-fold increase in serum levels with repeated dosing. Serum concentrations in patients with RA have not been measured for periods of dosing that exceed 6 months.

Pharmacokinetic parameters were not different between men and women and did not vary with age in adult patients. No formal pharmacokinetic studies have been conducted to examine the effects of renal or hepatic impairment or interactions with methotrexate.

Pediatric patients with JRA (ages 4 to 17 years) were administered 0.4 mg/kg of ENBREL for up to 18 weeks. The average serum concentration after repeated dosing was 2.1 mcg/mL, with a range of 0.7 to 4.3 mcg/mL. Preliminary data suggests that the clearance of ENBREL is reduced slightly in children ages 4 to 8 years. Children < 4 years of age have not been studied.

## CLINICAL STUDIES

## Adult Rheumatoid Arthritis

The safety and efficacy of ENBREL were assessed in three randomized, double-blind, controlled studies. Study I evaluated 234 patients with active RA who were  $\geq$  18 years old, had failed therapy with at least one but no more than four disease-modifying antirheumatic drugs (DMARDs; e.g., hydroxychloroquine, oral or injectable gold, methotrexate [MTX], azathioprine, D-penicillamine, sulfasalazine), and had  $\geq$  12 tender joints,  $\geq$  10 swollen joints, and either ESR  $\geq$  28 mm/hr, CRP  $>$  20 mg/dL, or morning stiffness for  $\geq$  45 minutes. Doses of 10 mg or 25 mg ENBREL or placebo were administered SC twice a week for 6 consecutive months. Results from patients receiving 25 mg are presented below.

Study II evaluated 89 patients and had similar inclusion criteria to Study I except that subjects in Study II had additionally received MTX for at least 6 months with a stable dose (12.5 to 25 mg/wk) for at least 4 weeks and they had at least 6 tender or painful joints. Subjects in Study II received a dose of 25 mg ENBREL or placebo SC twice a week for 6 months in addition to their stable MTX dose.

Study III compared the efficacy of ENBREL to MTX in patients with active RA. This study evaluated 632 patients who were  $\geq$  18 years old with early ( $\leq$  3 years disease duration) active RA; had never received treatment with MTX; and had  $\geq$  12 tender joints,  $\geq$  10 swollen joints, and either ESR  $\geq$  28 mm/hr, CRP  $>$  2.0 mg/dL, or morning stiffness for  $\geq$  45 minutes. Doses of 10 mg or 25 mg ENBREL were administered SC twice a week for 12 consecutive months. Results from patients receiving 25 mg are presented below. MTX tablets (escalated from 7.5 mg/week to a maximum of 20 mg/week over the first 8 weeks of the trial) or placebo tablets were given once a week on the same day as the injection of placebo or ENBREL doses, respectively.

The results of all three trials were expressed in percentage of patients with improvement in RA using American College of Rheumatology (ACR) response criteria.<sup>7</sup>

## Clinical Response

The percent of ENBREL-treated patients achieving ACR 20, 50, and 70 responses was consistent across all three trials. The results of the three trials are summarized in Table 1. (See table 1 above)

The time course for ACR 20 response rates for patients receiving placebo or 25 mg ENBREL in Studies I and II is summarized in Figure 1. The time course of responses to ENBREL in Study III was similar. (See figure 1 in next column)

Among patients receiving ENBREL, the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly always occurred by 3 months. A dose response was seen in Studies I and III: 25 mg ENBREL was more effective than 10 mg (10 mg was not evaluated in Study II). ENBREL was significantly better than placebo in

Table 1: ACR Responses in Placebo- and Active-Controlled Trials (Percent of Patients)

Response	Placebo Controlled				Active Control	
	Study I		Study II		Study III	
	Placebo N = 80	ENBREL <sup>a</sup> N = 78	MTX/ Placebo N = 30	MTX/ ENBREL <sup>a</sup> N = 59	MTX N = 217	ENBREL <sup>a</sup> N = 217
<b>ACR 20</b>						
Month 3	23%	62% <sup>b</sup>	33%	66% <sup>b</sup>	56%	65%
Month 6	11%	59% <sup>b</sup>	27%	71% <sup>b</sup>	58%	65%
Month 12	NA	NA	NA	NA	65%	65%
<b>ACR 50</b>						
Month 3	8%	41% <sup>b</sup>	0%	42% <sup>b</sup>	24%	32%
Month 6	5%	40% <sup>b</sup>	3%	39% <sup>b</sup>	32%	43%
Month 12	NA	NA	NA	NA	43%	43%
<b>ACR 70</b>						
Month 3	4%	15% <sup>b</sup>	0	15% <sup>b</sup>	7%	14%
Month 6	1%	15% <sup>b</sup>	0	15% <sup>b</sup>	14%	22%
Month 12	NA	NA	NA	NA	22%	22%

a. 25 mg ENBREL SC twice weekly.

b.  $p < 0.01$ , ENBREL vs. placebo.

c.  $p < 0.05$ , ENBREL vs. MTX.

Table 2: Components of ACR Response in Study I

Parameter (median)	Placebo N = 80		ENBREL <sup>a</sup> N = 78	
	Baseline	3 Months	Baseline	3 Months
Number of tender joints <sup>b</sup>	34.0	29.5	31.2	20.0
Number of swollen joints <sup>b</sup>	24.0	22.0	23.5	15.0
Physician global assessment <sup>d</sup>	7.0	6.5	7.0	5.0
Patient global assessment <sup>d</sup>	7.0	7.0	7.0	5.0
Pain <sup>d</sup>	6.9	6.6	6.9	5.0
Disability index <sup>e</sup>	1.7	1.8	1.6	1.0
ESR (mm/hour)	31.0	32.0	28.0	15.5
CRP (mg/dL)	2.8	3.9	3.5	0.9

\* Results at 6 months showed similar improvement.

a. 25 mg ENBREL SC twice weekly.

b. Scale 0-71.

c. Scale 0-68.

d. Visual analog scale; 0 = best, 10 = worst.


e. Health Assessment Questionnaire<sup>8</sup>; 0 = best, 3 = worst; includes eight categories: dressing and grooming, arising, walking, hygiene, reach, grip, and activities.

f.  $p < 0.01$ , ENBREL vs. placebo, based on mean percent change from baseline.

Table 3: Mean Radiographic Change Over 6 and 12 Months in Study III

		MTX		25 mg ENBREL		MTX-ENBREL	
						(95% Confidence Interval) <sup>a</sup>	
12 Months	Total Sharp score	1.59	1.00	0.59	(-0.12, 1.30)		
	Erosion score	1.03	0.47	0.56	(0.11, 1.00)		
	JSN score	0.56	0.52	0.04	(-0.39, 0.46)		
6 Months	Total Sharp score	1.06	0.57	0.49	(0.06, 0.91)		
	Erosion score	0.68	0.30	0.38	(0.09, 0.66)		
	JSN score	0.38	0.27	0.11	(-0.14, 0.35)		

\* 95% confidence intervals for the differences in change scores between MTX and ENBREL.



all components of the ACR criteria as well as other measures of RA disease activity not included in the ACR response criteria, such as morning stiffness.

In Study III, approximately 10% of patients treated with ENBREL achieved a major clinical response, defined as maintenance of an ACR 70 response over a 6-month period. The results of the components of the ACR response criteria for Study I are shown in Table 2. Findings were similar in Studies II and III for patients treated with ENBREL. (See table 2 above)

After discontinuation of ENBREL, symptoms of arthritis generally returned within a month. Reintroduction of treatment with ENBREL after discontinuations of up to 18 months resulted in the same magnitudes of response as pa-

tients who received ENBREL without interruption. Data based on results of open-label studies. Continued responses have been seen for up to 36 months after label extension treatment trials when patients received ENBREL without interruption.

A Health Assessment Questionnaire (HAQ) included disability, vitality, mental health, general health, and arthritis-associated health status subscores administered every 3 months during Studies I and II. Subdomains of the HAQ were improved in patients with ENBREL.

In Study III, health outcome measures were assessed using SF-36 questionnaire. The eight subscales of the SF-36 combined into two summary scales, the physical component summary (PCS) and the mental component summary (MCS).<sup>9</sup> At 12 months, patients treated with ENBREL showed significantly more improvement in PCS compared to the 10 mg ENBREL group, but not in MCS.

## Radiographic Response

In Study III, structural joint damage was assessed radiographically and expressed as change in total score (TSS) and its components, the erosion score and joint space narrowing (JSN) score. Radiographs of hands and forefeet were read at baseline, 6 months, and 12 months. The results are shown in Table 3. A significant change in erosion score was observed at 6 months and at 12 months.

(See table 3 above)

**Polyarticular-Course Juvenile Rheumatoid Arthritis**  
The safety and efficacy of ENBREL were assessed in a part study in 69 children with polyarticular-course JRA. The children had a variety of JRA onset types. Patients aged 1 to 16 years with moderately to severely active polyarticular-course JRA refractory to or intolerant of methotrexate were included. Patients remained on a stable dose of a single anti-inflammatory drug and/or prednisone ( $\leq$  0.5 mg/kg or 10 mg maximum). In part 1, all patients

BEST AVAILABLE COPY

(maximum 25 mg per dose) ENBREL SC twice daily. In part 2, patients with a clinical response at day 90 were randomized to remain on ENBREL or receive placebo for 6 months and assessed for disease flare. Responses were measured using the JRA Definition of Improvement defined as  $\geq 30\%$  improvement in at least three of the following criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and ESR. Disease flare was defined as  $\geq 30\%$  worsening in three of the six JRA core set criteria and  $\geq 30\%$  improvement in not more than one of the JRA core set criteria and a minimum of two active joints. In part 1 of the study, 51 of 69 (74%) patients demonstrated clinical response and entered part 2.<sup>11</sup> In part 2, 6 of 25 patients remaining on ENBREL experienced a disease flare compared to 20 of 26 (77%) patients receiving placebo ( $p = 0.007$ ). From the start of part 2, the median time to disease flare was  $\geq 116$  days for patients who received ENBREL and 28 days for patients who received placebo. Each component of the JRA core set criteria worsened in the arm that received placebo and remained stable or improved in the arm that continued on ENBREL. The data suggested the possibility of a higher flare rate among those patients with a baseline ESR. Of patients who demonstrated a clinical response at 90 days and entered part 2 of the study, 10 of the patients remaining on ENBREL continued to improve from month 3 through month 7, while those who received placebo did not improve.

The majority of JRA patients who developed a disease flare in part 2 and reintroduced ENBREL treatment up to 4 months after discontinuation re-responded to ENBREL therapy in open-label studies. Most of the responding patients who continued ENBREL therapy without interruption have maintained responses for up to 18 months.

Studies have not been done in patients with polyarticular JRA to assess the effects of continued ENBREL therapy in patients who do not respond within 3 months of initial ENBREL therapy, or to assess the combination of ENBREL with methotrexate.

**Immunogenicity**

Patients were tested at multiple timepoints for antibodies to ENBREL. Antibodies to ENBREL, all non-neutralizing, were detected at least once in sera of  $< 16\%$  of adult rheumatoid arthritis patients. No apparent correlation of antibody development to clinical response or adverse events was observed. Results from JRA patients were similar to those from adult RA patients treated with ENBREL. The long-term immunogenicity of ENBREL is unknown.

Results reflect the percentage of patients whose test results were considered positive for antibodies to ENBREL in the ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed percentage of antibody positivity in an assay may be influenced by several factors including sample handling, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ENBREL to the incidence of antibodies to other products may be difficult.

**INDICATIONS AND USAGE**

ENBREL is indicated for reducing signs and symptoms and for structural damage in patients with moderately to severely active rheumatoid arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more DMARDs.

**CONTRAINDICATIONS**

ENBREL should not be administered to patients with sepsis or known hypersensitivity to ENBREL or any of its components.

**WARNINGS**

MARKETING REPORTS, SERIOUS INFECTIONS, AND OTHER ADVERSE REACTIONS HAVE BEEN REPORTED WITH THE USE OF ENBREL. MANY OF THESE SERIOUS REACTIONS HAVE OCCURRED IN PATIENTS WITH UNDERLYING CONDITIONS THAT IN ADDITION TO THEIR RHEUMATOID ARTHRITIS COULD PREDISPOSE THEM TO SERIOUS INFECTIONS.

PATIENTS WHO DEVELOP A NEW INFECTION WHILE UNDERGOING TREATMENT WITH ENBREL SHOULD BE MONITORED CLOSELY. ADMINISTRATION OF ENBREL SHOULD BE DISCONTINUED IF A PATIENT DEVELOPS A SERIOUS INFECTION OR SEPSIS. TREATMENT WITH ENBREL SHOULD NOT BE INITIATED IN PATIENTS WITH SERIOUS INFECTIONS INCLUDING CHRONIC OR LOW-LEVEL INFECTIONS. PHYSICIANS SHOULD EXERCISE CAUTION WHEN CONSIDERING THE USE OF ENBREL IN PATIENTS WITH A HISTORY OF RECURRING INFECTIONS.

UNDERLYING CONDITIONS WHICH MAY PREDISPOSE PATIENTS TO INFECTIONS, SUCH AS ADVANCED CHRONIC DISEASES (SEE PRECAUTIONS, ADVERSE REACTIONS, Infections).

**PRECAUTIONS**

Reactions associated with administration of ENBREL in clinical trials have been reported in  $< 2\%$  of patients. An anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated.

**ADVERSE REACTIONS**

In clinical trials, the most common adverse reactions associated with administration of ENBREL were injection site reactions, upper respiratory infection, and headache.

In clinical trials, the most common adverse reactions associated with administration of ENBREL were injection site reactions, upper respiratory infection, and headache.

In clinical trials, the most common adverse reactions associated with administration of ENBREL were injection site reactions, upper respiratory infection, and headache.

In clinical trials, the most common adverse reactions associated with administration of ENBREL were injection site reactions, upper respiratory infection, and headache.

In clinical trials, the most common adverse reactions associated with administration of ENBREL were injection site reactions, upper respiratory infection, and headache.

In clinical trials, the most common adverse reactions associated with administration of ENBREL were injection site reactions, upper respiratory infection, and headache.

Table 4: Percent of RA Patients Reporting Adverse Events in Controlled Clinical Trials\*

Event	Placebo Controlled		Active Controlled (Study III)	
	Percent of patients		Percent of patients	
	Placebo† (n = 152)	ENBREL (n = 349)	MTX (n = 217)	ENBREL (n = 415)
Injection site reaction	10	37	7	34
Infection	32	35	72	64
Non-upper respiratory infection**	32	38	60	51
Upper respiratory infection**	16	29	39	31
Headache	13	17	27	24
Nausea	10	9	29	15
Rhinitis	8	12	14	16
Dizziness	5	7	11	8
Pharyngitis	5	7	9	6
Cough	3	6	6	5
Asthenia	3	5	12	11
Abdominal pain	3	5	10	10
Rash	3	5	23	14
Peripheral edema	3	2	4	8
Respiratory disorder	1	5	NA	NA
Dyspepsia	1	4	10	11
Sinusitis	2	3	3	5
Vomiting	—	3	8	5
Mouth ulcer	1	2	14	6
Alopecia	1	1	12	6
Pneumonitis ('MTX lung')	—	—	2	0

\* Includes data from the 6-month study in which patients received concurrent MTX therapy.

† The duration of exposure for patients receiving placebo was less than the ENBREL-treated patients.

\*\* Includes data from two placebo-controlled trials.

#### Information to Patients

If a patient or caregiver is to self-administer ENBREL, he/she should be instructed in injection techniques and how to measure the correct dose to help ensure the proper administration of ENBREL (see How to Use ENBREL, Instructions for Preparing and Giving an Injection). The first injection should be performed under the supervision of a qualified health-care professional. The patient's or caregiver's ability to self-inject subcutaneously should be assessed. A puncture-resistant container for disposal of needles and syringes should be used. Patients and caregivers should be instructed in the technique as well as proper syringe and needle disposal, and be cautioned against reuse of these items.

#### Immunosuppression

The possibility exists for anti-TNF therapies, including ENBREL, to affect host defenses against infections and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a study of 49 patients with RA treated with ENBREL, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations. The impact of treatment with ENBREL on the development and course of malignancies as well as active and/or chronic infections is not fully understood (see WARNINGS, ADVERSE REACTIONS, Infections and Malignancies). The safety and efficacy of ENBREL in patients with immunosuppression or chronic infections have not been evaluated.

#### Immunizations

No data are available on the effects of vaccination in patients receiving ENBREL. Live vaccines should not be given concurrently with ENBREL. No data are available on the secondary transmission of infection by live vaccines in patients receiving ENBREL (see PRECAUTIONS, Immunosuppression).

It is recommended that JRA patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating ENBREL therapy. Two JRA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella virus should temporarily discontinue ENBREL therapy and be considered for prophylactic treatment with Varicella Zoster Immune Globulin.

#### Autoantibody Formation

Treatment with ENBREL may result in the formation of auto-immune antibodies (see ADVERSE REACTIONS, Autoantibodies).

#### Drug Interactions

Specific drug interaction studies have not been conducted with ENBREL.

#### Carcinogenesis, Mutagenesis, and Impairment of Fertility

Long-term animal studies have not been conducted to evaluate the carcinogenic potential of ENBREL or its effect on fertility. Mutagenesis studies were conducted in vitro and in vivo, and no evidence of mutagenic activity was observed.

#### Pregnancy (Category B)

Developmental toxicity studies have been performed in rats and rabbits at doses ranging from 60- to 100-fold higher than the human dose and have revealed no evidence of harm to the fetus due to ENBREL. There are, however, no studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

#### Nursing Mothers

It is not known whether ENBREL is excreted in human milk or absorbed systemically after ingestion. Because

many drugs and immunoglobulins are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from ENBREL, a decision should be made whether to discontinue nursing or to discontinue the drug.

#### Geriatric Use

A total of 197 RA patients ages 65 years or older have been studied in clinical trials. No overall differences in safety or effectiveness were observed between these patients and younger patients. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly.

#### Pediatric Use

ENBREL is indicated for treatment of polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more DMARDs. For issues relevant to pediatric patients, in addition to other sections of the label, see also PRECAUTIONS, Immunizations, and ADVERSE REACTIONS, Adverse Reactions in Pediatric Patients. ENBREL has not been studied in children  $< 4$  years of age.

#### ADVERSE REACTIONS

ENBREL has been studied in 1197 patients with RA, followed for up to 36 months. The proportion of patients who discontinued treatment due to adverse events was approximately 4% in both ENBREL and placebo-treated patients.

#### Injection Site Reactions

In controlled trials, 37% of patients treated with ENBREL developed injection site reactions. All injection site reactions were described as mild to moderate (erythema and/or itching, pain, or swelling) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given.

#### Infections

In controlled trials, there were no differences in rates of infection among patients treated with ENBREL and those treated with placebo or MTX. The most common type of infection was upper respiratory infection, which occurred in 16% of placebo-treated patients and 29% of patients treated with ENBREL. When the longer observation of patients on ENBREL was accounted for, the event rate was similar in both groups.

In placebo-controlled trials in DMARD-refractory RA, no increase in the incidence of serious infections was observed (approximately 1% in both placebo and ENBREL-treated groups). The rates of infections for the ENBREL arm in Study III were similar. In all clinical trials in RA, 50 of 1197 subjects exposed to ENBREL for up to 36 months experienced serious infections, including pyelonephritis, bronchitis, septic arthritis, abdominal abscess, cellulitis, osteomyelitis, wound infection, pneumonia, foot abscess, leg ulcer, diarrhea, sinusitis, and sepsis. Serious infections, including sepsis and death, have also been reported during post-marketing use of ENBREL. Some have occurred within a few weeks after initiating treatment with ENBREL. Many of the patients had underlying conditions (e.g., diabetes, congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis. (See WARNINGS). Data from a sepsis clinical trial not specifically in patients with RA suggest that ENBREL treatment may increase mortality in patients with established sepsis.<sup>12</sup>

Continued on next page

## Enbrel—Cont.

## Malignancies

Seventeen malignancies of various types were observed in 1197 RA patients treated in clinical trials with ENBREL for up to 36 months. The observed rates and incidences were similar to those expected for the population studied.

## Autoantibodies

Patients had serum samples tested for autoantibodies at multiple timepoints. In Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed new positive ANA ( $\geq 1:40$ ) was higher in patients treated with ENBREL (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with ENBREL compared to 4% of placebo-treated patients) and by crithidia luciliae assay (3% of patients treated with ENBREL compared to none of placebo-treated patients). The proportion of patients treated with ENBREL who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In Study III, no pattern of increased autoantibody development was seen in ENBREL patients compared to MTX patients. No patients in placebo- and active-controlled trials developed clinical signs suggestive of a lupus-like syndrome. The impact of long-term treatment with ENBREL on the development of autoimmune diseases is unknown.

## Other Adverse Reactions

Table 4 summarizes events reported in at least 3% of all patients with higher incidence in patients treated with ENBREL compared to controls in placebo-controlled RA trials (including the combination methotrexate trial) and relevant events from Study III.

[See table 4 at top of previous page]

Among patients with rheumatoid arthritis treated in placebo-controlled trials, serious adverse events occurred at a frequency of 4% in 349 patients treated with ENBREL compared to 5% of 152 placebo-treated patients. In Study III, serious adverse events occurred at a frequency of 6% in 415 patients treated with ENBREL compared to 8% of 217 MTX-treated patients. Among patients with RA in placebo-controlled, active-controlled, and open-label trials of ENBREL, malignancies (see ADVERSE REACTIONS, Malignancies) and infections (see ADVERSE REACTIONS, Infections) were the most common serious adverse events observed. Other infrequent serious adverse events observed included heart failure, myocardial infarction, myocardial ischemia, cerebral ischemia, hypertension, hypotension, cholecystitis, pancreatitis, gastrointestinal hemorrhage, bursitis, depression, dyspnea, deep vein thrombosis, pulmonary embolism, membranous glomerulonephropathy, polymyositis, and thrombophlebitis.

## Adverse Reactions in Pediatric Patients

In general, the adverse events in pediatric patients were similar in frequency and type as those seen in adult patients. Differences from adult and other special considerations are discussed in the following paragraphs. Severe adverse reactions reported in 69 JRA patients ages 4 to 17 years included varicella (see also PRECAUTIONS, Immunizations), gastroenteritis, depression/personality disorder, cutaneous ulcer, esophagitis/gastritis, group A streptococcal septic shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.

Forty-three of 69 (62%) children with JRA experienced an infection while receiving ENBREL during three months of study (part 1 open-label), and the frequency and severity of infections was similar in 58 patients completing 12 months of open-label extension therapy. The types of infections reported in JRA patients were generally mild and consistent with those commonly seen in outpatient pediatric populations.

The following adverse events were reported more commonly in 69 JRA patients receiving 3 months of ENBREL compared to the 349 adult RA patients in placebo-controlled trials. These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 events per patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per patient year).

## OVERDOSAGE

The maximum tolerated dose of ENBREL has not been established in humans. Toxicology studies have been performed in monkeys at doses up to 30 times the human dose with no evidence of dose-limiting toxicities. No dose-limiting toxicities have been observed during clinical trials of ENBREL. Single IV doses up to 60 mg/m<sup>2</sup> have been administered to healthy volunteers in an endotoxemia study without evidence of dose-limiting toxicities. The highest dose level evaluated in RA patients has been a single IV loading dose of 32 mg/m<sup>2</sup> followed by SC doses of 16 mg/m<sup>2</sup> (~25 mg) administered twice weekly. In one RA trial, one patient mistakenly self-administered 62 mg ENBREL SC twice weekly for 3 weeks without experiencing adverse effects.

## DOSAGE AND ADMINISTRATION

The recommended dose of ENBREL for adult patients with rheumatoid arthritis is 25 mg given twice weekly as a subcutaneous injection 72–96 hours apart (see Clinical Studies). Methotrexate, glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics may be continued during treatment with ENBREL. Higher doses of ENBREL have not been studied.

The recommended dose of ENBREL for pediatric patients ages 4 to 17 years with active polyarticular-course JRA is

0.4 mg/kg (up to a maximum 25 mg per dose) given twice weekly as a subcutaneous injection 72–96 hours apart. Glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), or analgesics may be continued during treatment with ENBREL. Concurrent use with methotrexate and higher doses of ENBREL have not been studied in pediatric patients.

## Preparation of ENBREL

ENBREL is intended for use under the guidance and supervision of a physician. Patients may self-inject only if their physician determines that it is appropriate and with medical follow-up, as necessary, after proper training in how to measure the correct dose and in injection technique.

**Note:** The needle cover of the diluent syringe contains dry natural rubber (latex), which should not be handled by persons sensitive to this substance.

ENBREL should be reconstituted aseptically with 1 mL of the supplied Sterile Bacteriostatic Water for Injection, USP (0.9% benzyl alcohol) giving a solution of 1.0 mL containing 25 mg of ENBREL. During reconstitution of ENBREL, the diluent should be injected very slowly into the vial. Some foaming will occur. This is normal. To avoid excessive foaming, do not shake or vigorously agitate. The contents should be swirled gently during dissolution. Generally, dissolution of ENBREL takes less than 10 minutes. The reconstituted solution should be clear and colorless and used within 6 hours (see Storage and Stability).

Visually inspect the solution for particulate matter and discoloration prior to administration. The solution should not be used if discolored or cloudy, or if particulate matter remains. Withdraw the solution into a syringe, removing only the dose to be given from the vial. Some foam or bubbles may remain in the vial.

No other medications should be added to solutions containing ENBREL, and do not reconstitute ENBREL with other diluents. Do not filter reconstituted solution during preparation or administration.

Rotate sites for injection (thigh, abdomen, or upper arm). New injections should be given at least one inch from an old site and never into areas where the skin is tender, bruised, red, or hard. (See How to Use ENBREL, Instructions for Preparing and Giving an Injection instruction sheet.)

## Storage and Stability

Do not use a dose tray beyond the date stamped on the carton, dose tray label, vial label, or diluent syringe label. The dose tray containing ENBREL (sterile powder) must be refrigerated at 2–8°C (36–46°F). DO NOT FREEZE.

Administer reconstituted solutions of ENBREL as soon as possible after reconstitution. If not administered immediately after reconstitution, ENBREL may be stored in the vial at 2–8°C (36–46°F) for up to 6 hours. **ANY ENBREL NOT USED WITHIN 6 HOURS OF RECONSTITUTION SHOULD BE DISCARDED. PRODUCT STABILITY AND STERILITY CAN NOT BE ASSURED.**

## HOW SUPPLIED

ENBREL is supplied in a carton containing four dose trays (NDC 58406-425-34). Each dose tray contains one 25 mg single-use vial of etanercept, one syringe (1 mL Sterile Bacteriostatic Water for Injection, USP, containing 0.9% benzyl alcohol), one plunger, and two alcohol swabs.

## Rx only

## REFERENCES

- Feldman M, Brennan FM, Maini RN. The role of cytokines in rheumatoid arthritis. *Ann Rev Immunol* 1996;14:397.
- Grom A, Murray KF, Luyrink L, et al. Patterns of expression of tumor necrosis factor  $\alpha$ , tumor necrosis factor  $\beta$ , and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthritis. *Arthritis Rheum* 1996;39:1703.
- Saxne T, Palladino Jr MA, Heinegard D, et al. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. *Arthritis Rheum* 1988;31:1041.
- Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. *Cell* 1994;75:959.
- Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. *J Immunol* 1993;151:6602.
- Data on file, Immunex Corporation.
- Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;38:727.
- Ramey DR, Fries JF, Singh G. The Health Assessment Questionnaire 1995 – Status and Review. In: Spilker B, ed. *Quality of Life and Pharmacoeconomics in Clinical Trials*. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996.
- Ware JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. *J Clin Epidemiol* 1998;51(11):903–12.
- Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. *Arthr Rheum* 1997;40(7):1202.
- Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. *N Engl J Med* 2000;342(11):763–9.
- Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. *N Engl J Med* 1996;334(26):1697.

0311-04 Issue Date 06/2000

Manufactured by:  
Immunex Corporation  
Seattle, Washington 98101  
U.S. License Number 1132  
Marketed by Immunex Corporation and  
Pharmaceuticals  
© 2000 Immunex Corporation  
Immunex U.S. Patent Numbers:  
5,605,690; 5,712,155; 5,395,760; 5,945,397

LEUKINE®  
SARGRAMOSTIM

**Caution:** Federal law prohibits dispensing without prescription.

## DESCRIPTION

LEUKINE® (sargramostim) is a recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant DNA technology (*S. cerevisiae*) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. LEUKINE is a glycoprotein of 127 amino acids characterized by molecular species having molecular masses of 16,800 and 15,500 daltons. The amino acid sequence of LEUKINE differs from the natural human GM-CSF by substitution of leucine at position 23, and the C-terminal moiety may be different from the native protein. Sargramostim has been selected as the proper name for the derived rhu GM-CSF.

The LEUKINE Liquid presentation is formulated as a sterile, preserved (1.1% benzyl alcohol), injectable solution (250 mcg/mL) in a vial. Lyophilized LEUKINE is a sterile, preservative-free powder (250 mcg) that requires reconstitution with 1 mL Sterile Water for Injection, USP or Bacteriostatic Water for Injection, USP.

LEUKINE Liquid and reconstituted lyophilized LEUKINE are clear, colorless liquids suitable for subcutaneous or intravenous infusion. LEUKINE Liquid contains 250 mcg (2.8 × 10<sup>6</sup> IU/mL) sargramostim and 1.1% benzyl alcohol in a 1 mL solution. The vial of lyophilized LEUKINE contains 250 mcg (1.4 × 10<sup>6</sup> IU/vial) sargramostim. LEUKINE Liquid vial and reconstituted lyophilized LEUKINE vial also contain 40 mg/mL mannitol, USP; 2 mg/mL sucrose, NF; and 1.2 mg/mL tromethamine, USP. Biological potency is expressed in International Units (IU) as tested against the WHO First International Standard. The specific activity of LEUKINE is approximately 5.6 × 10<sup>6</sup> IU/mg.

## CLINICAL PHARMACOLOGY

**General** GM-CSF belongs to a group of growth-related colony stimulating factors which support clonal expansion, and differentiation of hematopoietic progenitor cells. GM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways.

GM-CSF is also capable of activating mature granulocytes and macrophages. GM-CSF is a multilineage factor in addition to dose-dependent effects on the myeloid lineage, can promote the proliferation of megakaryocytes and erythroid progenitors. However, other factors are required to induce complete maturation in these two lineages. The various cellular responses (i.e., division, maturation) are induced through GM-CSF binding to receptors expressed on the cell surface of target cells.

**In vitro Studies of LEUKINE in Human Cells** The activity of GM-CSF is species-specific. Consequently, *in vitro* studies have been performed on human cells to determine the pharmacological activity of LEUKINE. Exposure of human bone marrow cells to LEUKINE concentrations ranging from 1–100 ng/mL results in the generation of hematopoietic progenitors and in the formation of pure granulocyte, pure macrophage and mixed granulocyte-macrophage colonies.<sup>1</sup> Chemotactic, anti-fungal and parasitic activities of granulocytes and monocytes are increased by exposure to LEUKINE *in vitro*. LEUKINE increases the cytotoxicity of monocytes toward neoplastic cell lines<sup>2</sup> and activates polymorphonuclear leukocytes to inhibit the growth of tumor cells.

**In vivo Primate Studies of LEUKINE** Pharmacology studies of LEUKINE were performed in cynomolgus monkeys. An acute toxicity study revealed an LD<sub>50</sub> treatment-related toxicity following a single IV bolus at a dose of 300 mcg/kg. Two subacute studies were performed using IV injection (maximum dose 200 mcg/kg, 14 days) and subcutaneous injection (maximum dose 200 mcg/kg/day × 28 days). No major visceral organ toxicity was documented. Notable histopathology findings included increased cellularity in hematologic organs and lung tissues. A dose-dependent increase in leukocytes which consisted primarily of segmented neutrophils occurred during the dosing period; increases in monocytes, eosinophils and lymphocytes were also noted. Neutrophil counts decreased to pretreatment values over the week recovery period.

**Pharmacokinetics** Pharmacokinetic profiles have been analyzed in controlled studies of 24 normal male volunteers.

BEST AVAILABLE COPY

**Effexor-XR—Cont.**

There have been reports of elevated clozapine levels that were temporally associated with adverse events, including seizures, following the addition of venlafaxine. There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.

**DRUG ABUSE AND DEPENDENCE****Controlled Substance Class**

Effexor XR (venlafaxine hydrochloride) extended-release capsules is not a controlled substance.

**Physical and Psychological Dependence**

*In vitro* studies revealed that venlafaxine has virtually no affinity for opiate, benzodiazepine, phenylcyclidine (PCP), or N-methyl-D-aspartate (NMDA) receptors.

Venlafaxine was not found to have any significant CNS stimulant activity in rodents. In primate drug discrimination studies, venlafaxine showed no significant stimulant or depressant abuse liability.

Discontinuation effects have been reported in patients receiving venlafaxine (see "DOSAGE AND ADMINISTRATION").

While venlafaxine has not been systematically studied in clinical trials for its potential for abuse, there was no indication of drug-seeking behavior in the clinical trials. However, it is not possible to predict on the basis of premarketing experience the extent to which a CNS active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of venlafaxine (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).

**OVERDOSAGE****Human Experience**

Among the patients included in the premarketing evaluation of Effexor XR, there were 2 reports of acute overdose with Effexor XR in depression trials, either alone or in combination with other drugs. One patient took a combination of 6 g of Effexor XR and 2.5 mg of lorazepam. This patient was hospitalized, treated symptomatically, and recovered without any untoward effects. The other patient took 2.85 g of Effexor XR. This patient reported paresthesia of all four limbs but recovered without sequelae.

There were 2 reports of acute overdose with Effexor XR in GAD trials. One patient took a combination of 0.75 g of Effexor XR and 200 mg of paroxetine and 50 mg of zolpidem. This patient was described as being alert, able to communicate, and a little sleepy. This patient was hospitalized, treated with activated charcoal, and recovered without any untoward effects. The other patient took 1.2 g of Effexor XR. This patient recovered and no other specific problems were found. The patient had moderate dizziness, nausea, numb hands and feet, and hot-cold spells 5 days after the overdose. These symptoms resolved over the next week.

Among the patients included in the premarketing evaluation with Effexor, there were 14 reports of acute overdose with venlafaxine, either alone or in combination with other drugs and/or alcohol. The majority of the reports involved ingestion in which the total dose of venlafaxine taken was estimated to be no more than several-fold higher than the usual therapeutic dose. The 3 patients who took the highest doses were estimated to have ingested approximately 6.75 g, 2.75 g, and 2.5 g. The resultant peak plasma levels of venlafaxine for the latter 2 patients were 6.24 and 2.35 µg/mL, respectively, and the peak plasma levels of O-desmethylvenlafaxine were 3.37 and 1.30 µg/mL, respectively. Plasma venlafaxine levels were not obtained for the patient who ingested 6.75 g of venlafaxine. All 14 patients recovered without sequelae. Most patients reported no symptoms. Among the remaining patients, somnolence was the most commonly reported symptom. The patient who ingested 2.75 g of venlafaxine was observed to have 2 generalized convulsions and a prolongation of QTc to 500 msec, compared with 405 msec at baseline. Mild sinus tachycardia was reported in 2 of the other patients.

In postmarketing experience, overdose with venlafaxine has occurred predominantly in combination with alcohol and/or other drugs. Electrocardiogram changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), sinus and ventricular tachycardia, bradycardia, hypotension, altered level of consciousness (ranging from somnolence to coma), seizures, vertigo, and death have been reported.

**Management of Overdosage**

Treatment should consist of those general measures employed in the management of overdosage with any antidepressant.

Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients.

Activated charcoal should be administered. Due to the large volume of distribution of venlafaxine, forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for venlafaxine are known.

In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting

a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the *Physicians' Desk Reference* (PDR).

**DOSAGE AND ADMINISTRATION**

Effexor XR should be administered in a single dose with food either in the morning or in the evening at approximately the same time each day. Each capsule should be swallowed whole with fluid and not divided, crushed, chewed, or placed in water.

**Initial Treatment****Depression**

For most patients, the recommended starting dose for Effexor XR is 75 mg/day, administered in a single dose. In the clinical trials establishing the efficacy of Effexor XR in moderately depressed outpatients, the initial dose of venlafaxine was 75 mg/day. For some patients, it may be desirable to start at 37.5 mg/day for 4 to 7 days, to allow new patients to adjust to the medication before increasing to 75 mg/day. While the relationship between dose and antidepressant response for Effexor XR has not been adequately explored, patients not responding to the initial 75 mg/day dose may benefit from dose increases to a maximum of approximately 225 mg/day. Dose increases should be in increments of up to 75 mg/day, as needed, and should be made at intervals of not less than 4 days, since steady state plasma levels of venlafaxine and its major metabolites are achieved in most patients by day 4. In the clinical trials establishing efficacy, upward titration was permitted at intervals of 2 weeks or more; the average doses were about 140–180 mg/day (see "Clinical Trials" under "CLINICAL PHARMACOLOGY").

It should be noted that, while the maximum recommended dose for moderately depressed outpatients is also 225 mg/day for Effexor (the immediate release form of venlafaxine), more severely depressed inpatients in one study of the development program for that product responded to a mean dose of 350 mg/day (range of 150 to 375 mg/day). Whether or not higher doses of Effexor XR are needed for more severely depressed patients is unknown; however, the experience with Effexor XR doses higher than 225 mg/day is very limited.

**Generalized Anxiety Disorder**

For most patients, the recommended starting dose for Effexor XR is 75 mg/day, administered in a single dose. In clinical trials establishing the efficacy of Effexor XR in outpatients with Generalized Anxiety Disorder (GAD), the initial dose of venlafaxine was 75 mg/day. For some patients, it may be desirable to start at 37.5 mg/day for 4 to 7 days, to allow new patients to adjust to the medication before increasing to 75 mg/day. Although a dose-response relationship for effectiveness in GAD was not clearly established in fixed-dose studies, certain patients not responding to the initial 75 mg/day dose may benefit from dose increases to a maximum of approximately 225 mg/day. Dose increases should be in increments of up to 75 mg/day, as needed, and should be made at intervals of not less than 4 days.

**Switching Patients from Effexor Tablets**

Depressed patients who are currently being treated at a therapeutic dose with Effexor may be switched to Effexor XR at the nearest equivalent dose (mg/day), e.g., 37.5 mg venlafaxine two-times-a-day to 75 mg Effexor XR once daily. However, individual dosage adjustments may be necessary.

**Patients with Hepatic Impairment**

Given the decrease in clearance and increase in elimination half-life for both venlafaxine and ODV that is observed in patients with hepatic cirrhosis compared with normal subjects (see "CLINICAL PHARMACOLOGY"), it is recommended that the starting dose be reduced by 50% in patients with moderate hepatic impairment. Because there was much individual variability in clearance between patients with cirrhosis, individualization of dosage may be desirable in some patients.

**Patients with Renal Impairment**

Given the decrease in clearance for venlafaxine and the increase in elimination half-life for both venlafaxine and ODV that is observed in patients with renal impairment (GFR = 10–70 mL/min) compared with normal subjects (see "CLINICAL PHARMACOLOGY"), it is recommended that the total daily dose be reduced by 25%–50%. In patients undergoing hemodialysis, it is recommended that the total daily dose be reduced by 50% and that the dose be withheld until the dialysis treatment is completed (4 hrs). Because there was much individual variability in clearance between patients with renal impairment, individualization of dosage may be desirable in some patients.

**Elderly Patients**

No dose adjustment is recommended for elderly patients solely on the basis of age. As with any drug for the treatment of depression or generalized anxiety disorder, however, caution should be exercised in treating the elderly. When individualizing the dosage, extra care should be taken when increasing the dose.

**Maintenance/Extended Treatment**

There is no body of evidence available from controlled trials to indicate how long patients with depression or generalized anxiety disorder should be treated with Effexor XR.

It is generally agreed, however, that pharmacological treatment for acute episodes of depression should continue for up to six months or longer. Whether the dose of antidepressant needed to induce remission is identical to the dose needed to maintain euthymia is unknown.

In patients with Generalized Anxiety Disorder, there are no efficacy data beyond eight weeks of treatment with Effexor XR. The need for continuing medication in patients with GAD who improve with Effexor XR treatment should be periodically reassessed.

**Discontinuing Effexor XR**

When discontinuing Effexor XR after more than 1 week of therapy, it is generally recommended that the dose be tapered to minimize the risk of discontinuation symptoms. Patients who have received Effexor XR for 6 weeks or more should have their dose tapered over at least a 2-week period. In clinical trials with Effexor XR, tapering was achieved by reducing the daily dose by 75 mg at 1 week intervals. Individualization of tapering may be necessary. Discontinuation symptoms have been systematically evaluated in patients taking venlafaxine, to include prospective analyses of clinical trials in Generalized Anxiety Disorder and retrospective surveys of trials in depression. Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment. Reported symptoms include agitation, anorexia, anxiety, confusion, coordination impaired, diarrhea, dizziness, dry mouth, dysphoric mood, fasciculation, fatigue, headaches, hypomania, insomnia, nausea, nervousness, nightmares, sensory disturbances (including shock-like electrical sensations), somnolence, sweating, tremor, vertigo, and vomiting. It is therefore recommended that the dosage of Effexor XR be tapered gradually and the patient monitored. The period required for tapering may depend on the dose, duration of therapy and the individual patient. Discontinuation effects are well known to occur with antidepressants.

**Switching Patients To or From a Monoamine Oxidase Inhibitor**

At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with Effexor XR. In addition, at least 7 days should be allowed after stopping Effexor XR before starting an MAOI (see "CONTRAINDICATIONS" and "WARNINGS").

**HOW SUPPLIED**

Effexor XR (venlafaxine hydrochloride) extended-release capsules are available as follows:

37.5 mg, grey cap/peach body with "w" and "Effexor XR" on the cap and "37.5" on the body.

NDC 0008-0837-01, bottle of 100 capsules.

NDC 0008-0837-03, carton of 10 Redipak® blister strips of 10 capsules each.

Store at controlled room temperature, 20°C to 25°C (68°F to 77°F).

Bottles: Protect from light. Dispense in light-resistant container.

Blister: Protect from light. Use blister carton to protect contents from light.

75 mg, peach cap and body with "w" and "Effexor XR" on the cap and "75" on the body.

NDC 0008-0833-01, bottle of 100 capsules.

NDC 0008-0833-03, carton of 10 Redipak® blister strips of 10 capsules each.

Store at controlled room temperature, 20°C to 25°C (68°F to 77°F).

150 mg, dark orange cap and body with "w" and "Effexor XR" on the cap and "150" on the body.

NDC 0008-0836-01, bottle of 100 capsules.

NDC 0008-0836-03, carton of 10 Redipak® blister strips of 10 capsules each.

Store at controlled room temperature, 20°C to 25°C (68°F to 77°F).

The appearance of these capsules is a trademark of Wyeth-Ayerst Laboratories.

Manufactured by:

Wyeth Laboratories

A Wyeth-Ayerst Company

Philadelphia, PA 19101

CI 5044-5 Revised April 14, 2000

Shown in Product Identification Guide, page 341

**ENBREL®**

[en brel]

etanercept

**DESCRIPTION**

ENBREL (etanercept) is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the C<sub>2</sub> domain, the C<sub>3</sub> domain and hinge region, but not the C<sub>H</sub>1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 936 amino acids and has an apparent molecular weight of approximately 150 kilodaltons.

ENBREL is supplied as a sterile, white, preservative-free, lyophilized powder for parenteral administration after reconstitution with 1 mL of the supplied Sterile Bacteriostatic Water for Injection, USP (containing 0.9% benzyl alcohol). Following reconstitution, the solution of ENBREL is clear and colorless, with a pH of 7.4 ± 0.3. Each single-use vial of ENBREL contains 25 mg etanercept, 40 mg mannitol, 10 mg sucrose, and 1.2 mg tromethamine.

# CLINICAL PHARMACOLOGY

etanercept binds specifically to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors. TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It plays an important role in the inflammatory processes of rheumatoid arthritis (RA), polyarticular-course juvenile rheumatoid arthritis (JRA) and the resulting joint pathology.<sup>1,2</sup> Elevated levels of TNF are found in the synovial fluid of RA patients.<sup>3</sup> Two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75), exist naturally as monomeric molecules on cell surfaces and in soluble forms.<sup>4</sup> Biological activity of TNF is dependent upon binding to either cell surface TNFR.

etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules. It inhibits the activity of TNF in vitro and has been shown to affect several animal models of inflammation, including murine collagen-induced arthritis.<sup>5,6</sup> Etanercept inhibits binding of both TNF- $\alpha$  and TNF- $\beta$  (lymphotoxin  $\alpha$  [LT $\alpha$ ]) to cell surface TNFRs, rendering TNF biologically inactive.<sup>6</sup> Cells expressing transmembrane TNF that bind ENBREL are not lysed in vitro in the presence or absence of complement.<sup>5</sup>

etanercept can also modulate biological responses that are induced or regulated by TNF, including expression of adhesion molecules responsible for leukocyte migration (i.e., E-selectin and to a lesser extent intercellular adhesion molecule-1 [ICAM-1]), serum levels of cytokines (e.g., IL-6), and serum levels of matrix metalloproteinase-3 (MMP-3 or stromelysin).<sup>6</sup>

**Pharmacokinetics**  
After administration of 25 mg of ENBREL by a single subcutaneous (SC) injection to three patients with RA, a mean half-life of 115 hours (range 98 to 300 hours) was observed with a clearance of 89 mL/hr (52 mL/hr/m<sup>2</sup>). A maximum serum concentration (C<sub>max</sub>) of 1.2 mcg/mL (range 0.6 to 1.5 mcg/mL) and time to C<sub>max</sub> of 72 hours (range 48 to 108 hours) was observed in these patients. After continued dosing of RA patients (N = 25) with ENBREL for 6 months at 25 mg twice weekly, the median observed level was 1.7 mcg/mL (range 1.7 to 5.6 mcg/mL). Based on the available data, individual patients may undergo a two- to five-fold increase in serum levels with repeated dosing. Serum concentrations in patients with RA have not been measured during periods of dosing that exceed 6 months.

Pharmacokinetic parameters were not different between men and women and did not vary with age in adult patients. Formal pharmacokinetic studies have been conducted to examine the effects of renal or hepatic impairment or interactions with methotrexate. Pediatric patients with JRA (ages 4 to 17 years) were administered 0.4 mg/kg of ENBREL for up to 18 weeks. The average serum concentration after repeated dosing was 1.1 mcg/mL, with a range of 0.7 to 4.3 mcg/mL. Preliminary data suggest that the clearance of ENBREL is reduced slightly in children ages 4 to 8 years. Children <4 years of age have not been studied.

## CLINICAL STUDIES

**Adult Rheumatoid Arthritis**  
The safety and efficacy of ENBREL were assessed in two randomized, double-blind, controlled studies. Study I evaluated 234 patients with active RA who were  $\geq 18$  years old, did not respond to therapy with at least one but no more than four disease-modifying antirheumatic drugs (DMARDs; e.g., hydroxychloroquine, oral or injectable gold, methotrexate, TNF, azathioprine, D-penicillamine, sulfasalazine), and did not have  $\geq 12$  tender joints,  $\geq 10$  swollen joints, and either ESR  $\geq 28$  mm/hr, CRP  $> 2.0$  mg/dL, or morning stiffness for  $\geq 30$  minutes. Doses of 10 mg or 25 mg ENBREL or placebo were administered SC twice a week for 6 consecutive months. Results from patients receiving 25 mg are presented below.

Study II evaluated 89 patients with similar inclusion criteria to Study I except that subjects in Study II had additionally received MTX for at least 6 months with a stable dose of 15 to 25 mg/week for at least 4 weeks and they had at least one tender or painful joint. Subjects in Study II received a dose of 25 mg ENBREL or placebo SC twice a week for 6 months in addition to their stable MTX dose.

Study III compared the efficacy of ENBREL to MTX in patients with active RA. This study evaluated 632 patients who were  $\geq 18$  years old with early ( $\leq 3$  years disease duration) active RA; had never received treatment with MTX; did not have  $\geq 12$  tender joints,  $\geq 10$  swollen joints, and either ESR  $\geq 28$  mm/hr, CRP  $> 2.0$  mg/dL, or morning stiffness for  $\geq 45$  minutes. Doses of 10 mg or 25 mg ENBREL were administered SC twice a week for 12 consecutive months. Results from patients receiving 25 mg are presented below. CX tablets (escalated from 7.5 mg/week to a maximum of 15 mg/week over the first 8 weeks of the trial) or placebo tablets were given once a week on the same day as the initiation of placebo or ENBREL doses, respectively.

The results of all 3 trials were expressed in percentage of patients with improvement in RA using American College of Rheumatology (ACR) response criteria.<sup>7</sup>

### ACR Response

The percentage of ENBREL-treated patients receiving ACR 20, 50, and 70 responses was consistent across all 3 trials. The results of the three trials are summarized in Table 1 (see Table 1 above).

The time course for ACR 20 response rates for patients receiving placebo or 25 mg ENBREL in Studies I and II is

**Table 1**  
ACR Responses in Placebo- and Active-Controlled Trials (Percent of Patients)

Response	Placebo Controlled				Active Controlled	
	Study I		Study II		Study III	
	Placebo N = 80	ENBREL <sup>a</sup> N = 78	MTX/Placebo N = 30	MTX/ENBREL <sup>a</sup> N = 59	MTX N = 217	ENBREL <sup>a</sup> N = 207
<b>ACR 20</b>						
Month 3	23%	62% <sup>b</sup>	33%	66% <sup>b</sup>	56%	62%
Month 6	11%	59% <sup>b</sup>	27%	71% <sup>b</sup>	58%	65%
Month 12	NA	NA	NA	NA	65%	72%
<b>ACR 50</b>						
Month 3	8%	41% <sup>b</sup>	0%	42% <sup>b</sup>	24%	29%
Month 6	5%	40% <sup>b</sup>	3%	39% <sup>b</sup>	32%	40%
Month 12	NA	NA	NA	NA	43%	49%
<b>ACR 70</b>						
Month 3	4%	15% <sup>b</sup>	0	15% <sup>b</sup>	7%	13% <sup>c</sup>
Month 6	1%	15% <sup>b</sup>	0	15% <sup>b</sup>	14%	21% <sup>c</sup>
Month 12	NA	NA	NA	NA	22%	25%

<sup>a</sup> 25 mg ENBREL SC twice weekly.

<sup>b</sup>  $p < 0.01$ , ENBREL vs. placebo.

<sup>c</sup>  $p < 0.05$ , ENBREL vs. MTX.

**Table 2**  
Components of ACR Response in Study I

Parameter (median)	Placebo N = 80		ENBREL <sup>a</sup> N = 78	
	Baseline	3 Months	Baseline	3 Months <sup>a</sup>
Number of tender joints <sup>b</sup>	34.0	29.5	31.2	10.0 <sup>f</sup>
Number of swollen joints <sup>c</sup>	24.0	22.0	23.5	12.6 <sup>f</sup>
Physician global assessment <sup>d</sup>	7.0	6.5	7.0	3.0 <sup>f</sup>
Patient global assessment <sup>d</sup>	7.0	7.0	7.0	3.0 <sup>f</sup>
Pain <sup>d</sup>	6.9	6.6	6.9	2.4 <sup>f</sup>
Disability index <sup>e</sup>	1.7	1.8	1.6	1.0 <sup>f</sup>
ESR (mm/hr)	31.0	32.0	28.0	15.5 <sup>f</sup>
CRP (mg/dL)	2.8	3.9	3.5	0.9 <sup>f</sup>

<sup>a</sup> Results at 6 months showed similar improvement.

<sup>b</sup> 25 mg ENBREL SC twice weekly.

<sup>c</sup> Scale 0-71.


<sup>d</sup> Scale 0-68.

<sup>e</sup> Visual analog scale; 0 = best, 10 = worst.

<sup>f</sup> Health assessment questionnaire; 0 = best, 3 = worst; includes eight categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.

<sup>g</sup>  $p < 0.01$ , ENBREL vs. placebo, based on mean percent change from baseline.

summarized in Figure 1. The time course of responses to ENBREL in Study III were similar.



Among patients receiving ENBREL, the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly always occurred by 3 months. A dose response was seen in Studies I and III; 25 mg ENBREL was more effective than 10 mg (10 mg was not evaluated in Study II). ENBREL was significantly better than placebo in all components of the ACR criteria as well as other measures of RA disease activity not included in the ACR response criteria, such as morning stiffness.

In Study III, approximately 10% of patients treated with ENBREL achieved a major clinical response, defined as maintenance of an ACR 70 response over a 6-month period. The results of the components of the ACR response criteria for Study I are shown in Table 2. Findings were similar in Studies II and III for patients treated with ENBREL. (See Table 2 above.)

After discontinuation of ENBREL, symptoms of arthritis generally returned within a month. Reintroduction of treatment with ENBREL after discontinuations of up to 18 months resulted in the same magnitudes of response as patients who received ENBREL without interruption of therapy based on results of open-label studies. Continued durable responses have been seen for up to 36 months in open-label extension treatment trials when patients received ENBREL without interruption.

A Health Assessment Questionnaire (HAQ)<sup>8</sup> which included disability, vitality, mental health, general health sta-

tus, and arthritis-associated health status subdomains, was administered every 3 months during Studies I and III. All subdomains of the HAQ were improved in patients treated with ENBREL.

In Study III, health outcome measures were assessed by the SF-36 questionnaire. The eight subscales of the SF-36 were combined into two summary scales, the physical component summary (PCS) and the mental component summary (MCS).<sup>9</sup> At 12 months, patients treated with 25 mg ENBREL showed significantly more improvement in the PCS compared to the 10 mg ENBREL group, but not in the MCS.

### Radiographic Response

In Study III, structural joint damage was assessed radiographically and expressed as change in total Sharp score (TSS) and its components, the erosion score and joint space narrowing (JSN) score. Radiographs of hands/wrists and forefeet were read at baseline, 6 months, and 12 months. The results are shown in Table 3. A significant difference for change in erosion score was observed at 6 months and maintained at 12 months.

(See Table 3 at top of next page.)

### Polyarticular-Course Juvenile Rheumatoid Arthritis (JRA)

The safety and efficacy of ENBREL were assessed in a two-part study of 69 children with polyarticular-course JRA who had a variety of JRA onset types. Patients ages 4 to 17 years with moderately to severely active polyarticular-course JRA refractory to or intolerant of methotrexate were enrolled; patients remained on a stable dose of a single nonsteroidal anti-inflammatory drug and/or prednisone ( $\leq 0.2$  mg/kg/day or 10 mg maximum). In part 1, all patients received 0.4 mg/kg (maximum 25 mg per dose) ENBREL SC twice weekly. In part 2, patients with a clinical response at day 90 were randomized to remain on ENBREL or receive placebo for four months and assessed for disease flare. Responses were measured using the JRA Definition of Improvement (DOI),<sup>10</sup> defined as  $\geq 30\%$  improvement in at least three of six and  $\geq 30\%$  worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and ESR. Disease flare was defined as a  $\geq 30\%$  worsening in three of six JRA core set criteria and  $\geq 30\%$  improvement in no more than one of six JRA core set criteria and a minimum of two active joints.

In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2.<sup>11</sup> In part 2, 6 of 25 (24%) patients remaining on ENBREL experienced a disease flare compared to 20 of 26 (77%) patients receiving placebo ( $p=0.007$ ). From the start of part 2, the median time to flare was  $\geq 116$  days for patients who received ENBREL and 28 days for patients who received placebo. Each component of the JRA core set criteria worsened in the arm that

Continued on next page



## el-Cont.

lived placebo and remained stable or improved in the a.m. that continued on ENBREL. The data suggested the possibility of a higher flare rate among those patients with a higher baseline ESR. Of patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the patients remaining on ENBREL continued to improve from month 3 through month 7, while those who received placebo did not improve.

The majority of JRA patients who developed a disease flare in part 2 and reintroduced ENBREL treatment up to 4 months after discontinuation re-responded to ENBREL therapy, in open-label studies. Most of the responding patients who continued ENBREL therapy without interruption have maintained responses for up to 18 months. Studies have not been done in patients with polyarticular-course JRA to assess the effects of continued ENBREL therapy in patients who do not respond within 3 months of initiating ENBREL therapy, or to assess the combination of ENBREL with methotrexate.

**Immunogenicity**

Patients were tested at multiple timepoints for antibodies to ENBREL. Antibodies to ENBREL, all non-neutralizing, were detected at least once in sera of 16% of adult rheumatoid arthritis patients. No apparent correlation of antibody development to clinical response or adverse events was observed. Results from JRA patients were similar to those seen in adult RA patients treated with ENBREL. The long-term immunogenicity of ENBREL is unknown.

The data reflect the percentage of patients whose test results were considered positive for antibodies to ENBREL in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ENBREL with the incidence of antibodies to other products may be misleading.

**INDICATIONS AND USAGE**

ENBREL is indicated for reducing signs and symptoms and delaying structural damage in patients with moderately to severely active rheumatoid arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more DMARDs.

**CONTRAINDICATIONS**

ENBREL should not be administered to patients with sepsis or with known hypersensitivity to ENBREL or any of its components.

**WARNINGS**

**IN POST-MARKETING REPORTS, SERIOUS INFECTIONS AND SEPSIS, INCLUDING FATALITIES, HAVE BEEN REPORTED WITH THE USE OF ENBREL. MANY OF THESE SERIOUS EVENTS HAVE OCCURRED IN PATIENTS WITH UNDERLYING DISEASES THAT IN ADDITION TO THEIR RHEUMATOID ARTHRITIS COULD PREDISPOSE THEM TO INFECTIONS. PATIENTS WHO DEVELOP A NEW INFECTION WHILE UNDERGOING TREATMENT WITH ENBREL SHOULD BE MONITORED CLOSELY. ADMINISTRATION OF ENBREL SHOULD BE DISCONTINUED IF A PATIENT DEVELOPS A SERIOUS INFECTION OR SEPSIS. TREATMENT WITH ENBREL SHOULD NOT BE INITIATED IN PATIENTS WITH ACTIVE INFECTIONS, INCLUDING CHRONIC OR LOCALIZED INFECTIONS. PHYSICIANS SHOULD EXERCISE CAUTION WHEN CONSIDERING THE USE OF ENBREL IN PATIENTS WITH A HISTORY OF RECURRING INFECTIONS, OR WITH UNDERLYING CONDITIONS WHICH MAY PREDISPOSE PATIENTS TO INFECTIONS, SUCH AS ADVANCED OR POORLY CONTROLLED DIABETES (see PRECAUTIONS, ADVERSE REACTIONS, Infections).**

**PRECAUTIONS****General**

Allergic reactions associated with administration of ENBREL during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated.

**Information to Patients**

If a patient or caregiver is to self-administer ENBREL, he/she should be instructed in injection techniques and how to measure the correct dose to help ensure the proper administration of ENBREL (see How to Use ENBREL, Instructions for Preparing and Giving an Injection.) The first injection should be performed under the supervision of a qualified health care professional. The patient's or caregiver's ability to self-inject subcutaneously should be assessed. A puncture-resistant container for disposal of needles and syringes should be used. Patients and caregivers should be instructed in the technique as well as proper syringe and needle disposal, and be cautioned against reuse of these items.

**Immunosuppression**

The possibility exists for anti-TNF therapies, including ENBREL, to affect host defenses against infections and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a study of 49 patients with

**Table 3**  
Mean Radiographic Change Over 6 and 12 Months in Study III  
MTX - ENBREL  
(95% Confidence Interval)<sup>a</sup>

		MTX	25 mg Enbrel	MTX - ENBREL (95% Confidence Interval) <sup>a</sup>	P value
12 Months	Total Sharp score	1.59	1.00	0.59 (-0.12, 1.30)	0.110
	Erosion score	1.03	0.47	0.56 (0.11, 1.00)	0.002
	JSN score	0.56	0.52	0.04 (-0.39, 0.46)	0.529
6 Months	Total Sharp score	1.06	0.57	0.49 (0.06, 0.91)	0.001
	Erosion score	0.68	0.30	0.38 (0.09, 0.66)	0.001
	JSN score	0.38	0.27	0.11 (-0.14, 0.35)	0.588

<sup>a</sup> 95% confidence intervals for the differences in change scores between MTX and ENBREL.

RA treated with ENBREL, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations. The impact of treatment with ENBREL on the development and course of malignancies, as well as active and/or chronic infections is not fully understood (see **WARNINGS, ADVERSE REACTIONS, Infections and Malignancies**). The safety and efficacy of ENBREL in patients with immunosuppression or chronic infections have not been evaluated.

**Immunizations**

No data are available on the effects of vaccination in patients receiving ENBREL. Live vaccines should not be given concurrently with ENBREL. No data are available on the secondary transmission of infection by live vaccines in patients receiving ENBREL (see **PRECAUTIONS, Immunosuppression**).

It is recommended that JRA patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating ENBREL therapy. Two JRA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella virus should temporarily discontinue ENBREL therapy and be considered for prophylactic treatment with Varicella Zoster Immune Globulin.

**Autoantibody Formation**

Treatment with ENBREL may result in the formation of auto-immune antibodies (see **ADVERSE REACTIONS, Autoantibodies**).

**Drug Interactions**

Specific drug interactions studies have not been conducted with ENBREL.

**Carcinogenesis, Mutagenesis, and Impairment of Fertility**

Long-term animal studies have not been conducted to evaluate the carcinogenic potential of ENBREL or its effect on fertility. Mutagenesis studies were conducted in vitro and in vivo, and no evidence of mutagenic activity was observed.

**Pregnancy (Category B)**

Developmental toxicity studies have been performed in rats and rabbits at doses ranging from 60- to 100-fold higher than the human dose and have revealed no evidence of harm to the fetus due to ENBREL. There are, however, no studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Nursing Mothers**

It is not known whether ENBREL is excreted in human milk or absorbed systemically after ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from ENBREL, a decision should be made whether to discontinue nursing or to discontinue the drug.

**Geriatric Use**

A total of 197 RA patients ages 65 years or older have been studied in clinical trials. No overall differences in safety or effectiveness were observed between these patients and younger patients. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly.

**Pediatric Use**

ENBREL is indicated for treatment of polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more DMARDs. For issues relevant to pediatric patients, in addition to other sections of the label, see also **PRECAUTIONS, Immunizations, and ADVERSE REACTIONS, Adverse Reactions in Pediatric Patients**. ENBREL has not been studied in children < 4 years of age.

**ADVERSE REACTIONS**

ENBREL has been studied in 1197 patients with RA, followed for up to 36 months. The proportion of patients who discontinued treatment due to adverse events was approximately 4% in both ENBREL and placebo-treated patients.

**Injection Site Reactions**

In controlled trials, 37% of patients treated with ENBREL developed injection site reactions. All injection site reactions were described as mild to moderate (erythema and/or itching, pain, or swelling) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given.

**Infections**

In controlled trials, there were no differences in rates of infection among patients treated with ENBREL and those

treated with placebo or MTX. The most common type of infection was upper respiratory infection, which occurred in 16% of placebo-treated patients and 29% of patients treated with ENBREL. When the longer observation of patients on ENBREL was accounted for, the event rate was similar in both groups.

In placebo-controlled trials in DMARD-refractory RA, no increase in the incidence of serious infections was observed (approximately 1% in both placebo and ENBREL-treated groups). The rates of infections for the ENBREL arm in Study III were similar. In all clinical trials in RA, 50 of 1197 subjects exposed to ENBREL for up to 36 months experienced serious infections, including pyelonephritis, bronchitis, septic arthritis, abdominal abscess, cellulitis, osteomyelitis, wound infection, pneumonia, foot abscess, leg ulcer, diarrhea, sinusitis, and sepsis. Serious infections, including sepsis and death, have also been reported during postmarketing use of ENBREL. Some have occurred within a few weeks after initiating treatment with ENBREL. Many of the patients had underlying conditions (e.g., diabetes, congestive heart failure, history of active or chronic infection) in addition to their rheumatoid arthritis (see **WARNINGS, Malignancies**). Data from a sepsis clinical trial not specifically in patients with RA suggest that ENBREL treatment may increase mortality in patients with established sepsis.

**Malignancies**

Seventeen malignancies of various types were observed in 1197 RA patients treated in clinical trials with ENBREL for up to 36 months. The observed rates and incidences were similar to those expected for the population studied.

**Autoantibodies**

Patients had serum samples tested for autoantibodies at multiple timepoints. In Studies I and II, the percentage of the patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed new positive ANA ( $\geq 1:40$ ) was higher in patients treated with ENBREL (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (11% of patients treated with ENBREL compared to 4% of placebo-treated patients) and by crithidia luciliae assay (3% of patients treated with ENBREL compared to none of placebo-treated patients). The proportion of patients treated with ENBREL who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In Study III, no pattern of increased autoantibody development was seen in ENBREL patients compared to MTX patients.

No patients in placebo- and active-controlled trials developed clinical signs suggestive of a lupus-like syndrome. The impact of long-term treatment with ENBREL on the development of autoimmune diseases is unknown.

**Other Adverse Reactions**

Table 4 summarizes events reported in at least 3% of all patients with higher incidence in patients treated with ENBREL compared to controls in placebo-controlled RA trials (including the combination methotrexate trial and relevant events from Study III).

(See table 4 at bottom of next page)  
Among patients with rheumatoid arthritis treated in placebo-controlled trials, serious adverse events occurred at a frequency of 4% in 349 patients treated with ENBREL compared to 5% of 152 placebo-treated patients. In Study III, serious adverse events occurred at a frequency of 6% in 417 patients treated with ENBREL compared to 8% of 217 MTX-treated patients. Among patients with RA in placebo-controlled, active-controlled, and open-label trials of ENBREL, malignancies (see **ADVERSE REACTIONS, Malignancies**) and infections (see **ADVERSE REACTIONS, Infections**) were the most common serious adverse events observed. Other infrequent serious adverse events observed included heart failure, myocardial infarction, myocardial ischemia, cerebral ischemia, hypertension, hypotension, cholecystitis, pancreatitis, gastrointestinal hemorrhage, bursitis, depression, dyspnea, deep vein thrombosis, pulmonary embolism, membranous glomerulonephropathy, polymyositis, and thrombophlebitis.

**Adverse Reactions in Pediatric Patients**

In general, the adverse events in pediatric patients were similar in frequency and type as those seen in adult patients. Differences from adults and other special considerations are discussed in the following paragraphs. Severe adverse reactions reported in 69 JRA patients ages 4 to 17 years included varicella (see also **PRECAUTIONS, Immunizations**), gastroenteritis, depression/personality disorder, cutaneous ulcer, esophagitis/gastritis, group A streptococcal septic shock, type I diabetes mellitus, and not because and post-operative wound infection. Forty-three of 69 (62%) children with JRA experienced an infection while receiving ENBREL during 3 months of study (part 1 open-label), and the frequency and severity of infection

BEST AVAILABLE COPY

tions was similar in 58 patients completing 12 months of open-label extension therapy. The types of infections reported in JRA patients were generally mild and consistent with those commonly seen in outpatient pediatric populations.

The following adverse events were reported more commonly in 69 JRA patients receiving 3 months of ENBREL compared to the 349 adult RA patients in placebo-controlled trials. These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 events per patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per patient year).

#### OVERDOSAGE

The maximum tolerated dose of ENBREL has not been established in humans. Toxicology studies have been performed in monkeys at doses up to 30 times the human dose with no evidence of dose-limiting toxicities. No dose-limiting toxicities have been observed during clinical trials of ENBREL. Single IV doses up to 60 mg/m<sup>2</sup> have been administered to healthy volunteers in an endotoxemia study without evidence of dose-limiting toxicities. The highest dose level evaluated in RA patients has been a single IV loading dose of 32 mg/m<sup>2</sup> followed by SC doses of 16 mg/m<sup>2</sup> (~25 mg) administered twice weekly. In one RA trial, one patient mistakenly self-administered 62 mg ENBREL SC twice weekly for 3 weeks without experiencing adverse effects.

#### DOSEAGE AND ADMINISTRATION

The recommended dose of ENBREL for adult patients with rheumatoid arthritis is 25 mg given twice weekly as a subcutaneous injection 72-96 hours apart (see Clinical Studies). Methotrexate, glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs), or analgesics may be continued during treatment with ENBREL. Higher doses of ENBREL have not been studied.

The recommended dose of ENBREL for pediatric patients ages 4 to 17 years with active polyarticular-course JRA is 0.4 mg/kg (up to a maximum 25 mg per dose) given twice weekly as a subcutaneous injection 72-96 hours apart. Glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), or analgesics may be continued during treatment with ENBREL. Concurrent use with methotrexate and higher doses of ENBREL have not been studied in pediatric patients.

#### Preparation of ENBREL

ENBREL is intended for use under the guidance and supervision of a physician. Patients may self-inject only if their physician determines that it is appropriate and with medical follow-up, as necessary, after proper training in how to measure the correct dose and in injection technique.

**Note:** The needle cover of the diluent syringe contains dry natural rubber (latex), which should not be handled by persons sensitive to this substance.

ENBREL should be reconstituted aseptically with 1 mL of the supplied Sterile Bacteriostatic Water for Injection, USP (0.9% benzyl alcohol) giving a solution of 1.0 mL containing 25 mg of ENBREL. During reconstitution of ENBREL, the diluent should be injected very slowly into the vial. Some foaming will occur. This is normal. To avoid excessive foaming, do not shake or vigorously agitate. The contents should be swirled gently during dissolution. Generally, dissolution of ENBREL takes less than 10 minutes. The reconstituted solution should be clear and colorless and used within 6 hours (see **Storage and Stability**).

Visually inspect the solution for particulate matter and discoloration prior to administration. The solution should not

be used if discolored or cloudy, or if particulate matter remains. Withdraw the solution into the syringe, removing only the dose to be given from the vial. Some foam or bubbles may remain in the vial.

No other medications should be added to solutions containing ENBREL, and do not reconstitute ENBREL with other diluents. Do not filter reconstituted solution during preparation or administration.

Rotate sites for self-injection (thigh, abdomen, or upper arm). New injections should be given at least one inch from an old site and never into areas where the skin is tender, bruised, red, or hard. (See **How to Use ENBREL, Instructions for Preparing and Giving an Injection** instruction sheet.)

#### Storage and Stability

Do not use a dose tray beyond the date stamped on the carton dose tray label, vial label, or diluent syringe label. The dose tray containing ENBREL (sterile powder) must be refrigerated at 2-8°C (36-46°F). DO NOT FREEZE.

Administer reconstituted solutions as soon as possible after reconstitution. If not administered immediately after reconstitution, ENBREL may be stored in the vial at 2-8°C (36-46°F) for up to 6 hours. **ANY ENBREL NOT USED WITHIN 6 HOURS OF RECONSTITUTION SHOULD BE DISCARDED. PRODUCT STABILITY AND STERILITY CANNOT BE ASSURED.**

#### HOW SUPPLIED

ENBREL is supplied in a carton containing four dose trays (NDC 58406-425-34). Each dose tray contains one 25 mg single-use vial of etanercept, one syringe (1 mL Sterile Bacteriostatic Water for Injection, USP, containing 0.9% benzyl alcohol), one plunger, and two alcohol swabs.

Rx only

#### REFERENCES

- Feldman M, Brennan FM, Maini RN. The role of cytokines in rheumatoid arthritis. *Ann Rev Immunol* 1996;14:397.
- Grom A, Murray KF, Luyrink L et al. Patterns of expression of tumor necrosis factor  $\alpha$ , tumor necrosis factor  $\beta$ , and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthritis. *Arthritis Rheum* 1996;39:1703.
- Saxne T, Palladino Jr MA, Heinegard D, et al. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. *Arthritis Rheum* 1998;31:1041.
- Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. *Cell* 1994;75:959.
- Woolley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. *J Immunol* 1993;151:6602.
- Data on file, Immunex Corporation.
- Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;6:727.
- Ramey DR, Fries JF, Singh G. The Health Assessment Questionnaire 1995 - Status and Review. In: Spilker B, ed. "Quality of Life and Pharmacoeconomics in Clinical Trials." 2nd ed. Philadelphia, PA. Lippincott-Raven;1996.
- Ware JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. *J Clin Epidemiol* 1998; 51(11):903-12.

Table 4  
Percent of RA Patients Reporting Adverse Events in Controlled Clinical Trials\*

Event	Placebo Controlled		Active Controlled (Study III)	
	Percent of patients	Percent of patients	Percent of patients	Percent of patients
	Placebo† (n = 152)	ENBREL (n = 349)	MTX (n = 217)	ENBREL (n = 415)
Injection site reaction	10	37	7	34
Infection	32	35	72	64
Non-upper respiratory infection**	32	38	60	51
Upper respiratory infection**	16	29	39	31
Headache	13	17	27	24
Nausea	10	9	29	15
Rhinitis	8	12	14	16
Dizziness	5	7	11	8
Pharyngitis	5	7	9	6
Cough	3	6	6	5
Asthenia	3	5	12	11
Abdominal Pain	3	5	10	10
Rash	3	5	23	14
Peripheral edema	3	2	4	8
Respiratory disorder	1	5	NA	NA
Dyspepsia	1	4	10	11
Sinusitis	2	3	3	5
Vomiting	-	3	8	5
Mouth ulcer	1	2	14	6
Alopecia	1	1	12	6
Pneumonitis ("MTX lung")	-	-	2	0

\* Includes data from the 6-month study in which patients received concurrent MTX therapy.

† The duration of exposure for patients receiving placebo was less than the ENBREL-treated patients.

\*\*Includes data from two of the three placebo controlled trials.

- Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. *Arthr Rheum* 1997;40(7):1202.
  - Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. *N Engl J Med* 2000; 342(11):763-9.
  - Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor fusion protein. *The Soluble TNF Receptor Sepsis Study Group. N Engl J Med* 1996;334(26):1697.
- 0311-04  
Issue Date 06/2000  
Manufactured by:  
Immunex Corporation  
Seattle, Washington 98101  
U.S. License Number 1132  
Marketed by Immunex Corporation and Wyeth-Ayerst Pharmaceuticals  
Immunex U.S. Patent Numbers:  
5,605,690; 5,712,155; 5,395,760; 5,945,397

#### EQUAGESIC®

[ek 'wa-jē 'zik]  
(meprobamate with aspirin)

#### DESCRIPTION

Each tablet of Equagesic contains 200 mg meprobamate and 325 mg aspirin. The inactive ingredients present are cellulose, D&C Yellow 10, FD&C Red 3, FD&C Yellow 6, hydrogenated vegetable oil, magnesium stearate, polacrillin potassium, and starch.

#### HOW SUPPLIED

Equagesic® (meprobamate with aspirin) Tablets, 200 mg meprobamate and 325 mg aspirin, are available as follows: NDC 0008-0091, pink and yellow, double-layer, round, scored tablet marked "WYETH" and "91", in bottles of 100 tablets.

Store at room temperature, approx. 25°C (77°F).

Keep tightly closed.

Protect from light.

Dispense in light-resistant, tight container.

The appearance of EQUAGESIC tablets is a registered trademark of Wyeth-Ayerst Laboratories.

Manufactured by:

Wyeth Laboratories Inc.  
A Wyeth-Ayerst Company  
Philadelphia, PA 19101

CI 3343-6 Revised November 18, 1994

For full prescribing information write to Professional Service, Wyeth-Ayerst Pharmaceuticals, P.O. Box 8299, Philadelphia, PA 19101, or contact your local Wyeth-Ayerst representative.

#### EQUANIL®

[ek 'wah-nīl]  
(meprobamate)  
Tablets

#### DESCRIPTION

Meprobamate is a white powder with a characteristic odor and a bitter taste. It is slightly soluble in water, freely soluble in acetone and alcohol, and sparingly soluble in ether. Equanil tablets contain 200 mg or 400 mg meprobamate. The inactive ingredients present are lactose, methylcellulose, polacrillin potassium, and stearic acid.

#### HOW SUPPLIED

Equanil® (meprobamate) Tablets are available in the following dosage strengths: 200 mg, NDC 0008-0002, white, five-sided tablet marked "WYETH" and "2", in bottles of 100 tablets.

400 mg, NDC 0008-0001, white, round, scored tablet marked "WYETH" and "1", in bottles of 100 and 500 tablets.

Keep tightly closed.

Dispense in tight container.

Store at room temperature, approximately 25°C (77°F).

Manufactured by:

Wyeth Laboratories Inc.  
A Wyeth-Ayerst Company  
Philadelphia, PA 19101

CI 3313-6 Revised January 18, 1994

For prescribing information write to Professional Service, Wyeth-Ayerst Pharmaceuticals, P.O. Box 8299, Philadelphia, PA 19101, or contact your local Wyeth-Ayerst representative.

#### FACTREL®

[fak-'trēl]  
(gonadorelin hydrochloride)  
Synthetic Luteinizing Hormone Releasing Hormone (LH-RH)  
DIAGNOSTIC USE ONLY

#### HOW SUPPLIED

LYOPHILIZED POWDER  
in single-dose Secule® vials containing 100 mcg (NDC 0046-0507-05) and 500 mcg (NDC 0046-0509-05) gonadorelin as

Continued on next page